WO2014207113A1 - Levures techniquement conçues pour la production de substances chimiques de valeur à partir de sucres - Google Patents

Levures techniquement conçues pour la production de substances chimiques de valeur à partir de sucres Download PDF

Info

Publication number
WO2014207113A1
WO2014207113A1 PCT/EP2014/063540 EP2014063540W WO2014207113A1 WO 2014207113 A1 WO2014207113 A1 WO 2014207113A1 EP 2014063540 W EP2014063540 W EP 2014063540W WO 2014207113 A1 WO2014207113 A1 WO 2014207113A1
Authority
WO
WIPO (PCT)
Prior art keywords
coa
cell
amino acid
acid sequence
seq
Prior art date
Application number
PCT/EP2014/063540
Other languages
English (en)
Inventor
Johannes Adrianus Maria De Bont
Andreas Raab
Michael Schilling
María Mercedes TAMAME GONZÁLEZ
María DE LOS ÁNGELES SANTOS GARCÍA
Vitor MARTINS DOS SANTOS
Ricardo ARJONA ANTOLÍN
Pablo GUTIÉRREZ GÓMEZ
Original Assignee
Abengoa Bioenergia Nuevas Tecnologias S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abengoa Bioenergia Nuevas Tecnologias S.A. filed Critical Abengoa Bioenergia Nuevas Tecnologias S.A.
Publication of WO2014207113A1 publication Critical patent/WO2014207113A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/16—Butanols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/02—Preparation of hydrocarbons or halogenated hydrocarbons acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/02—Preparation of hydrocarbons or halogenated hydrocarbons acyclic
    • C12P5/026—Unsaturated compounds, i.e. alkenes, alkynes or allenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01001—Alcohol dehydrogenase (1.1.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
    • C12Y102/04001—Pyruvate dehydrogenase (acetyl-transferring) (1.2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01054—Formate C-acetyltransferase (2.3.1.54), i.e. pyruvate formate-lyase or PFL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01001—Pyruvate decarboxylase (4.1.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • the present invention relates to the fields of fermentation and metabolic engineering of yeasts such as Saccharomyces cerevisiae.
  • the invention relates to S. cerevisiae strains that have been engineered to express in the absence of fatty acids several of the enzymes that are required in the degradation of such acids along with certain other enzymes.
  • the expression of some of the native yeast enzymes has been prevented in order to prevent the formation of undesired by-products.
  • the invention further relates to the processes wherein the engineered strains of the invention produce compounds from sugars.
  • Yeasts such as S. cerevisiae are known to be superior hosts in the industrial production from sugar of ethanol and of more valuable compounds as well.
  • a large number of metabolic routes in the production of a variety of compounds has been investigated in bacteria such as Escherichia coli.
  • bacteria will not be applied on industrial scales because of their many inherent drawbacks as compared to yeast. Consequently, bacteria-based processes will not lead to economically sound processes.
  • Yeasts on the other hand intrinsically pose technical challenges in constructing the desired production hosts via molecular approaches.
  • the present inventors have now surprisingly been able to successfully express in yeast metabolic routes that previously have been implemented in E. coli. Consequently, the production of a number of highly-relevant chemicals is now feasible on industrial scales.
  • Zhang et al (Current Opinion in Biotechnology 2011, 22:775-783) disclose that production of biofuels from renewable resources provides a source of liquid transportation fuel to replace petroleum-based fuels. This endeavor requires the conversion of cellulosic biomass into simple sugars, and the transformation of simple sugars into biofuels. Recently, microorganisms have been engineered to convert simple sugars into several types of biofuels, such as alcohols, fatty acid alkyl esters, alkanes, and terpenes, with high titers and yields. Several engineered metabolic pathways for the production of advanced bio fuels were reported.
  • Peralta-Yahya et al 2012, Nature, 488(7411):320-88) disclose that advanced biofuels produced by microorganisms have similar properties to petroleum-based fuels, and can 'drop in' to the existing transportation infrastructure. However, producing these biofuels in yields high enough to be useful requires the engineering of the microorganism's metabolism. Pathways for fatty-acid-derived fuels were quoted from published data.
  • Clomburg and Gonzalez disclose biofuel production in E. coli with an emphasis on metabolic engineering and synthetic biology.
  • Dellomonaco et al. disclose the engineered reversal of the ⁇ -oxidation cycle for the synthesis of fuels and chemicals in E. coli. They produced long-chain products via elongation of short-chain metabolites. They applied a reversal of the ⁇ -oxidation cycle as based on CoA-thioester intermediates that directly uses acetyl-CoA for acyl-chain elongation.
  • Zheng et al. disclose that they have studied the bioproduction of C12/C14 and C16/18 alcohols in E. coli. They improved the fatty alcohol production by systematically optimizing the fatty alcohol biosynthesis pathway, mainly by targeting three key steps from fatty acyl-acyl carrier proteins (ACPs) to fatty alcohols, which are sequentially catalyzed by thioesterase, acyl- coenzyme A (CoA) synthase and fatty acyl-CoA reductase.
  • ACPs fatty acyl-acyl carrier proteins
  • CoA acyl- coenzyme A
  • Mendez-Perez et al. disclose the production of traces of 1-alkenes as based on a polyketide synthetase in a Synechococcus strain. They suggest that the unsaturated hydrocarbons were produced from fatty acids via an elongation decarboxylation mechanism involving the so-termed Ols multi-domain enzyme.
  • Mendez-Perez et al (2012, Metabolic Engineering, 14:298-305) expressed the ols gene heterologously in E. coli but no production of an alkene was observed.
  • S. cerevisiae is a preferred host over E. coli but that their central metabolism are distinct from each other calling for novel metabolic engineering strategies in S. cerevisiae as compared to E. coli.
  • the invention pertains to a modified eukaryotic microbial host cell.
  • the host cell preferably is modified to comprise: a) cytosolic expression of the enzymes of the fatty acid ⁇ -oxidation cycle in the absence of fatty acids and in the presence of a non-fatty acid carbon source; b) a metabolic route for producing under oxic conditions and preferably in the cytosol, acetyl-CoA from the non-fatty acid carbon source to feed into and drive the ⁇ -oxidation cycle in the bio synthetic direction; and, c) expression of a termination enzyme to convert reaction intermediates of the ⁇ - oxidation cycle into at least one fermentation product selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans-A 2 -fatty acid, an alkene, an alkane and derivatives thereof.
  • the invention pertains to the use of a cell modified according to the invention, for the production of a fermentation product selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans-A 2 -fatty acid, an alkene, an alkane and derivatives thereof.
  • the invention relates to processes for producing a fermentation product, whereby the process comprises the steps of: a) fermenting a medium with a modified cell according to the invention under oxic conditions, whereby the medium contains or is fed with a non-fatty acid carbon source and whereby the yeast cell ferments the non-fatty acid carbon source to the fermentation product; and optionally, b) recovery of the fermentation product, wherein preferably the fermentation product selected from the group consisting of fermentation product selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans-A 2 -fatty acid, an alkene, an alkane and derivatives thereof.
  • Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences.
  • similarity between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity” and “similarity” can be readily calculated by known methods.
  • sequence identity or “sequence similarity” means that two (poly)peptide or two nucleotide sequences, when optimally aligned, preferably over the entire length (of at least the shortest sequence in the comparison) and maximizing the number of matches and minimizes the number of gaps such as by the programs ClustalW (1.83), GAP or BESTFIT using default parameters, share at least a certain percentage of sequence identity as defined elsewhere herein.
  • GAP uses the Needleman and Wunsch global alignment algorithm to align two sequences over their entire length, maximizing the number of matches and minimizes the number of gaps.
  • the default scoring matrix used is nwsgapdna and for proteins the default scoring matrix is Blosum62 (Henikoff & Henikoff, 1992, PNAS 89, 915-919).
  • a preferred multiple alignment program for aligning protein sequences of the invention is ClustalW (1.83) using a blosum matrix and default settings (Gap opening penalty: 10; Gap extension penalty: 0.05).
  • RNA sequences are said to be essentially similar or have a certain degree of sequence identity with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence.
  • Sequence alignments and scores for percentage sequence identity may be determined using computer programs, such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752 USA or the open-source software Emboss for Windows (current version 2.7.1- 07).
  • percent similarity or identity may be determined by searching against databases such as FASTA, BLAST, etc.
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al, Nucleic Acids Research 12 (1):387 (1984)), BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al, J. Mol. Biol. 215:403-410 (1990).
  • the BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al, NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al, J. Mol. Biol. 215:403-410 (1990).
  • the well-known Smith Waterman algorithm may also be used to determine identity.
  • Preferred parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89: 10915-10919 (1992); Gap Penalty: 12; and Gap Length Penalty: 4.
  • a program useful with these parameters is publicly available as the "Ogap" program from Genetics Computer Group, located in Madison, WI.
  • the aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps).
  • Preferred parameters for nucleic acid comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol.
  • amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide- containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine- valine, and asparagine-glutamine.
  • Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place.
  • the amino acid change is conservative.
  • Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gin or his; Asp to glu; Cys to ser or ala; Gin to asn; Glu to asp; Gly to pro; His to asn or gin; He to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
  • Nucleotide sequences of the invention may also be defined by their capability to hybridize with parts of specific nucleotide sequences disclosed herein, respectively, under moderate, or preferably under stringent hybridization conditions.
  • Stringent hybridization conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridize at a temperature of about 65 °C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at 65 °C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength.
  • the hybridization is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridization of sequences having about 90% or more sequence identity.
  • Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridize at a temperature of about 45 °C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength.
  • the hybridization is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution.
  • These conditions will usually allow the specific hybridization of sequences having up to 50% sequence identity. The person skilled in the art will be able to modify these hybridization conditions in order to specifically identify sequences varying in identity between 50% and 90%.
  • nucleic acid construct or “nucleic acid vector” is herein understood to mean a man-made nucleic acid molecule resulting from the use of recombinant DNA technology.
  • the term “nucleic acid construct” therefore does not include naturally occurring nucleic acid molecules although a nucleic acid construct may comprise (parts of) naturally occurring nucleic acid molecules.
  • expression vector or expression construct” refer to nucleotide sequences that are capable of affecting expression of a gene in host cells or host organisms compatible with such sequences. These expression vectors typically include at least suitable transcription regulatory sequences and optionally, 3' transcription termination signals. Additional factors necessary or helpful in effecting expression may also be present, such as expression enhancer elements.
  • the expression vector will be introduced into a suitable host cell and be able to effect expression of the coding sequence in an in vitro cell culture of the host cell.
  • the expression vector will be suitable for replication in the host cell or organism of the invention.
  • promoter or “transcription regulatory sequence” refers to a nucleic acid fragment that functions to control the transcription of one or more coding sequences, and is located upstream with respect to the direction of transcription of the transcription initiation site of the coding sequence, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter.
  • a “constitutive” promoter is a promoter that is active in most tissues under most physiological and developmental conditions.
  • An “inducible” promoter is a promoter that is physiologically or developmentally regulated, e.g. by the application of a chemical inducer.
  • selectable marker is a term familiar to one of ordinary skill in the art and is used herein to describe any genetic entity which, when expressed, can be used to select for a cell or cells containing the selectable marker.
  • reporter may be used interchangeably with marker, although it is mainly used to refer to visible markers, such as green fluorescent protein (GFP). Selectable markers may be dominant or recessive or bidirectional.
  • operably linked refers to a linkage of polynucleotide elements in a functional relationship.
  • a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • a transcription regulatory sequence is operably linked to a coding sequence if it affects the transcription of the coding sequence.
  • Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein encoding regions, contiguous and in reading frame.
  • protein or “polypeptide” are used interchangeably and refer to molecules consisting of a chain of amino acids, without reference to a specific mode of action, size, 3-dimensional structure or origin.
  • Fungi (singular fungus) are herein understood as heterotrophic eukaryotic microorganisms that digest their food externally, absorbing nutrient molecules into their cells. Fungi are a separate kingdom of eukaryotic organisms and include yeasts, molds, and mushrooms. The terms fungi, fungus and fungal as used herein thus expressly includes yeasts as well as filamentous fungi.
  • gene means a DNA fragment comprising a region (transcribed region), which is transcribed into an R A molecule (e.g. an mRNA) in a cell, operably linked to suitable regulatory regions (e.g. a promoter).
  • R A molecule e.g. an mRNA
  • a gene will usually comprise several operably linked fragments, such as a promoter, a 5' leader sequence, a coding region and a 3'-nontranslated sequence (3 'end) comprising a polyadenylation site.
  • “Expression of a gene” refers to the process wherein a DNA region which is operably linked to appropriate regulatory regions, particularly a promoter, is transcribed into an RNA, which is biologically active, i.e.
  • nucleic acid or polypeptide when used to indicate the relation between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain. If homologous to a host cell, a nucleic acid sequence encoding a polypeptide will typically (but not necessarily) be operably linked to another (heterologous) promoter sequence and, if applicable, another (heterologous) secretory signal sequence and/or terminator sequence than in its natural environment.
  • the regulatory sequences, signal sequences, terminator sequences, etc. may also be homologous to the host cell.
  • the use of only “homologous” sequence elements allows the construction of "self-cloned” genetically modified organisms (GMO's) (self-cloning is defined herein as in European Directive 98/81/EC Annex II).
  • GMO's genetically modified organisms
  • self-cloning is defined herein as in European Directive 98/81/EC Annex II.
  • the term "homologous" means that one single- stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later.
  • heterologous and exogenous when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature.
  • Heterologous and exogenous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but have been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins, i.e.
  • heterologous/exogenous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as foreign to the cell in which it is expressed is herein encompassed by the term heterologous or exogenous nucleic acid or protein.
  • heterologous and exogenous also apply to non-natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
  • the "specific activity" of an enzyme is herein understood to mean the amount of activity of a particular enzyme per amount of total host cell protein, usually expressed in units of enzyme activity per mg total host cell protein.
  • the specific activity of a particular enzyme may be increased or decreased as compared to the specific activity of that enzyme in an (otherwise identical) wild type host cell.
  • Oxic conditions or an aerobic or oxic fermentation process is herein defined as conditions or a fermentation process run in the presence of oxygen and in which oxygen is consumed, preferably at a rate of at least 0.5, 1, 2, 5, 10, 20 or 50 mmol/L/h, and wherein organic molecules serve as electron donor and oxygen serves as electron acceptor.
  • Any reference to nucleotide or amino acid sequences accessible in public sequence databases herein refers to the version of the sequence entry as available on the filing date of this document. Detailed description of the invention
  • E. coli has been engineered by constitutively expressing enzymes of the aerobic fatty acid ⁇ -oxidation cycle (the " ⁇ -oxidation cycle") in combination with expressing other relevant enzymes and by also removing certain enzyme activities that would lead to unwanted side products.
  • ⁇ -oxidation cycle constitutively expressing enzymes of the aerobic fatty acid ⁇ -oxidation cycle
  • Such engineered bacteria have been proposed as production organisms in the manufacturing from sugar of several chemicals (see e.g. Clomburg and Gonzalez et al. supra; Dellomonaco et al. supra; and Gulevich et al. supra).
  • the present inventors have found, however, that under relevant industrial conditions the production processes envisaged will be far from optimal due to the properties of the E. coli host. They have now found that it is possible to (constitutively) express all relevant genes for producing compounds via the reverse aerobic fatty acid ⁇ - oxidation cycle in yeasts such as S. cerevisiae. In combination with overexpressing and/or deleting enzymes, the present inventors have demonstrated that the industrially- relevant S. cerevisiae can be successfully employed in producing desired compounds under industrial conditions.
  • the invention relates to a eukaryotic microbial host cell, preferably a yeast host cell, that has the desired properties for industrial processes and that will be modified following standard molecular techniques.
  • a host cell of the invention preferably comprises the following features, which features may already be present in the host cell or which may be newly introduced and/or modified to be improved:
  • the host cell preferably functionally expresses (enzymes of) the fatty acid ⁇ - oxidation cycle, preferably in the cytosol of the host cell.
  • the ⁇ -oxidation cycle enzymes are expressed under conditions that include the presence of non-fatty acid carbon sources, i.e. carbohydrates (such as hexoses and disaccharides), including catabolite repressing carbon sources, and preferably also in the presence of oxygen (oxic/aerobic conditions).
  • the host cell preferably provides acetyl-CoA to feed into and drive the ⁇ - oxidation cycle in the reverse, i.e. biosynthetic direction.
  • the acetyl-CoA is preferably provided in the cytosol of the host cell via pyruvate that is obtained from a non-fatty acid carbon source, preferably through at least (the last) part of the glycolytic pathway.
  • the host preferably directs as much as possible of the carbon flow as acetyl- CoA into the reversed ⁇ -oxidation cycle. Reactions producing unwanted by-products (such as e.g. ethanol, acetate and/or acetaldehyde) as well as reactions that would compete for cytosolic acetyl-CoA with reversed ⁇ -oxidation cycle, are therefore preferably absent or modified so as to reduce or eliminate their activity in the host cell. These features are described in more detail under 2) herein.
  • the host cell preferably functionally expresses termination enzymes to convert reaction intermediates of the ⁇ -oxidation cycle into the desired end product, such as fatty acids, 1 -alcohols, ⁇ -ketoacids, ⁇ -ketoalcohols, ⁇ -hydroxyacids, 1 ,3-diols, trans- ⁇ 2 - fatty acids, alkanes, alkenes and/or derivatives thereof.
  • termination enzymes to convert reaction intermediates of the ⁇ -oxidation cycle into the desired end product, such as fatty acids, 1 -alcohols, ⁇ -ketoacids, ⁇ -ketoalcohols, ⁇ -hydroxyacids, 1 ,3-diols, trans- ⁇ 2 - fatty acids, alkanes, alkenes and/or derivatives thereof.
  • the present invention concerns the genetic modification of a host cell so as to enable the host cell to produce desired compounds via the reversal of the fatty acid ⁇ - oxidation pathway.
  • a number of genetic modifications will be introduced in a parent host cell in accordance with the invention. These modifications include the introduction of expression of a number of heterologous genes, as well as, the modification of the expression of a number of endogenous genes already present in the parent host cell, by reducing or inactivating the expression of some endogenous genes and/or by increasing, i.e. overexpressing, other endogenous genes.
  • a parent host cell is thus understood to be a host cell prior to that any of the genetic modifications in accordance with the invention have been introduced in the host cell.
  • a parent host cell of the invention preferably is a eukaryotic host cell, more preferably, the host cell is a eukaryotic microorganism such as e.g. a fungal host cell.
  • a most preferred parent host cell to be modified in accordance with the invention is a yeast host cell.
  • Yeasts are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Yeasts: characteristics and identification, J.A. Barnett, R.W. Payne, D. Yarrow, 2000, 3rd ed., Cambridge University Press, Cambridge UK; and, The yeasts, a taxonomic study, CP. Kurtzman and J.W. Fell (eds) 1998, 4th ed., Elsevier Science Publ. B.V., Amsterdam, The Netherlands) that predominantly grow in unicellular form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism.
  • Preferred yeasts cells for use in the present invention belong to the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Cryptococcus, Debaromyces, Saccharomycecopsis, Saccharomycodes, Wickerhamia, Debayomyces, Hanseniaspora, Ogataea, Kuraishia, Komagataella, Metschnikowia, Williopsis, Nakazawaea, Torulaspora, Bullera, Rhodotorula, and Sporobolomyces.
  • the parental yeast host cell is naturally capable of anaerobic fermentation, more preferably alcoholic fermentation and most preferably anaerobic alcoholic fermentation.
  • the host cell is modified to avoid or reduce the synthesis of ethanol.
  • yeasts such as Saccharomyces species
  • yeast species have many attractive features for industrial processes, including e.g. their high tolerance to acids, ethanol and other harmful compounds, their high osmo-tolerance and their capability of anaerobic growth, and of course their high fermentative capacity.
  • Preferred yeast species as parent host cells for the invention include e.g. Saccharomyces cerevisiae, S. exiguus, S. bayanus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei, S. lactis, S. marxianus, S. microellipsoides, S.
  • the parent host cell of the invention preferably contains active glycolysis.
  • the host cell further preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e. capable of growth at a pH lower than 5, 4, or 3) and towards organic acids like lactic acid, acetic acid or formic acid and sugar degradation products such as furfural and hydroxy-methylfurfural, and a high tolerance to elevated temperatures.
  • a high tolerance to ethanol i.e. capable of growth at a pH lower than 5, 4, or 3
  • organic acids like lactic acid, acetic acid or formic acid and sugar degradation products such as furfural and hydroxy-methylfurfural
  • a high tolerance to elevated temperatures a high tolerance to elevated temperatures.
  • a suitable cell is a cultured cell, a cell that may be cultured in fermentation process e.g. in submerged or solid state fermentation.
  • genetically modified (yeast) host strains may be carried out by genetic crosses, sporulation of the resulting diploids, tetrad dissection of the haploid spores containing the desired auxotrophic markers, and colony purification of such haploid host cells in the appropriate selection medium. All of these methods are standard fungal and yeast genetic methods known to those in the art. See, for example, Sherman et al, Methods Yeast Genetics, Cold Spring Harbor Laboratory, NY (1978) and Guthrie et al. (Eds.) Guide To Yeast Genetics and Molecular Biology Vol. 194, Academic Press, San Diego (1991).
  • suitable promoters for the expression of the heterologous nucleotide sequence coding for desired enzyme activities and/or for overexpression of endogenous genes in the context of the invention include promoters that are preferably insensitive to catabolite (glucose) repression, that are active at least under oxic (aerobic) and preferably also under anoxic (anaerobic) conditions and/or that preferably do not require specific carbon sources for induction. Promoters having these characteristics are widely available and known to the skilled person. Suitable examples of such promoters include e.g.
  • promoters from glycolytic genes such as the phosphofructokinase (PPK), triose phosphate isomerase ( ⁇ ), glyceraldehyde-3 -phosphate dehydrogenase (GPD, TDH3 or GAPDH), pyruvate kinase (PYK), phosphoglycerate kinase (PGK), glucoses- phosphate isomerase promoter (PGIl) promoters from yeasts. More details about such promoters from yeast may be found in (WO 93/03159).
  • PPK phosphofructokinase
  • ⁇ triose phosphate isomerase
  • GPD glyceraldehyde-3 -phosphate dehydrogenase
  • PYK pyruvate kinase
  • PGK phosphoglycerate kinase
  • PGIl glucoses- phosphate isomerase promoter
  • promoters are ribosomal protein encoding gene promoters (TEFI), the lactase gene promoter (LAC4), alcohol dehydrogenase promoters (ADHl, preferably a modified (constitutive) version of the ADHl promoter (SEQ ID NO: 86), ADH4, and the like), the enolase promoter (ENO) and the hexose(glucose) transporter promoter (HX 7).
  • Other promoters both constitutive and inducible, and enhancers or upstream activating sequences will be known to those of skill in the art.
  • the promoter that is operably linked to nucleotide sequence as defined above is homologous to the host cell.
  • Suitable terminator sequences are e.g. obtainable from the cytochrome cl (CYC1) gene or an alcohol dehydrogenase gene (e.g. ADHl).
  • the nucleotide sequence encoding of enzymes of the invention are preferably adapted to optimize their codon usage to that of the host cell in question.
  • the adaptiveness of a nucleotide sequence encoding an enzyme to the codon usage of a host cell may be expressed as codon adaptation index (CAI).
  • CAI codon adaptation index
  • the codon adaptation index is herein defined as a measurement of the relative adaptiveness of the codon usage of a gene towards the codon usage of highly expressed genes in a particular host cell or organism.
  • the relative adaptiveness (w) of each codon is the ratio of the usage of each codon, to that of the most abundant codon for the same amino acid.
  • CAI index is defined as the geometric mean of these relative adaptiveness values. Non-synonymous codons and termination codons (dependent on genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a higher proportion of the most abundant codons (see Sharp and Li , 1987, Nucleic Acids Research 15: 1281-1295; also see: Jansen et al, 2003, Nucleic Acids Res. 3J_(8):2242-51).
  • An adapted nucleotide sequence preferably has a CAI of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9. Most preferred are the sequences which have been codon optimized for expression in the fungal host cell in question such as e.g. S. cerevisiae cells.
  • the host cells of the invention are genetically modified so as to reduce or inactivate unwanted side reactions.
  • the endogenous pyruvate decarboxylase activity in the host cell is reduced or eliminated as a means to prevent the formation of at least one acetaldehyde, acetate and ethanol.
  • Endogenous pyruvate decarboxylase activity in yeast converts pyruvate to acetaldehyde, which is then converted to ethanol, or to acetyl-CoA via acetate (see Figure 1).
  • Yeasts may have one or more genes encoding pyruvate decarboxylase.
  • there is one gene encoding pyruvate decarboxylase in Kluyveromyces lactis while there are three isozymes of pyruvate decarboxylase encoded by the PDC1, PCD 5, and PDC6 (EC 4.1.1.1) genes in Saccharomyces cerevisiae, as well as a pyruvate decarboxylase regulatory gene PDC2.
  • the specific pyruvate decarboxylase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, under aerobic or anaerobic conditions.
  • the pyruvate decarboxylase activity can be reduced by modifying at least one gene encoding a pyruvate decarboxylase, or by modifying a gene regulating the expression of pyruvate decarboxylase gene(s).
  • the PDC1 and PDC5 genes, or all three genes can be modified to reduce or eliminate their expression e.g. by disruption.
  • pyruvate decarboxylase activity may be reduced by modification, e.g. disruption, of the PDC2 regulatory gene in S. cerevisiae.
  • genes to be modified for reducing the specific pyruvate decarboxylase activity in the cell of the invention are one or more or all of the S. cerevisiae PDC1, PDC5, PDC6 and PDC2 genes, encoding the amino acid sequences of SEQ ID NO's: 1, 2, 3 and 4, respectively, or orthologues thereof in other species. Therefore genes to be modified for reducing the specific pyruvate decarboxylase activity in the cell of the invention, preferably are one or more or all of the genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to one or more of SEQ ID NO's: 1, 2, 3 and 4, respectively.
  • yeast strains with reduced pyruvate decarboxylase activity due to disruption of pyruvate decarboxylase encoding genes have been reported for Saccharomyces in Flikweert et al. (Yeast (1996) 12:247-257), and disruption of the regulatory gene in Hohmann, (Mol Gen Genet. (1993) 241 :657-666). Saccharomyces strains having no pyruvate decarboxylase activity are available from the ATCC with accession no.'s #200027 and #200028.
  • Genes encoding pyruvate decarboxylases and/or PDC regulatory genes may be modified so as to reduce pyruvate decarboxylase specific activity in host cells of the invention using a variety of methods for genetic modification. Many methods for modifying endogenous target genes in host cells so as to reduce or eliminate the activity of the encoded target proteins are known to one skilled in the art and may be used for modifying the host cells of the invention. Modifications that may be used to reduce or eliminate expression of a target protein are disruptions that include, but are not limited to, deletion of the entire gene or a portion of the gene encoding the target protein (e.g.
  • a pyruvate decarboxylase inserting a DNA fragment into the target gene (in either the promoter or coding region) so that the protein is not expressed or expressed at lower levels, introducing a mutation into the target coding region which adds a stop codon or frame shift such that a functional protein is not expressed, and introducing one or more mutations into a target coding region to alter amino acids so that a non-functional target protein, or a target protein with reduced enzymatic activity is expressed.
  • expression of the target gene may be blocked by expression of an antisense R A or an interfering R A, and constructs may be introduced that result in co-suppression.
  • a target coding sequence may be synthesized whose expression will be low because rare codons are substituted for plentiful ones, when this suboptimal coding sequence is substituted for the corresponding endogenous target coding sequence.
  • a suboptimal coding sequence will have a codon adaptation index (see above) of less than 0.5, 0.4, 0.3 0.2, or 0.1.
  • Such a suboptimal coding sequence will produce the same polypeptide but at a lower rate due to inefficient translation.
  • the synthesis or stability of the transcript may be reduced by mutation.
  • the efficiency by which a protein is translated from mRNA may be modulated by mutation, e.g. by using suboptimal translation initiation codons. All of these methods may be readily practiced by one skilled in the art making use of the known or identified sequences encoding target proteins such as the pyruvate decarboxylase proteins.
  • DNA sequences flanking a target coding sequence such as the pyruvate decarboxylase coding sequences are also useful in some modification procedures and are available for yeasts such as for Saccharomyces cerevisiae in the complete genome sequence coordinated by Genome Project ID9518 of Genome Projects coordinated by NCBI (National Center for Biotechnology Information) with identification GOPID #13838.
  • DNA sequences surrounding a target coding sequence are useful for modification methods using homologous recombination.
  • sequences flanking the target gene are placed on either site of a selectable marker gene to mediate homologous recombination whereby the marker gene replaces the target gene.
  • partial target gene sequences and target gene flanking sequences bounding a selectable marker gene may be used to mediate homologous recombination whereby the marker gene replaces a portion of the target gene, e.g. a pyruvate decarboxylase gene.
  • the selectable marker may be flanked by site-specific recombination sites, so that following expression of the corresponding site-specific recombinase, the resistance gene is excised from the genomic locus where the target gene was present without reactivating the latter.
  • the site-specific recombination leaves behind a recombination site which disrupts expression of the target protein.
  • the homologous recombination vector may be constructed to also leave a deletion in the target gene following excision of the selectable marker, as is well known to one skilled in the art.
  • Deletions may be made using mitotic recombination as described in Wach et al. ((1994) Yeast 10: 1793-1808).
  • This method involves preparing a DNA fragment that contains a selectable marker between genomic regions that may be as short as 20 bp, and which bound, i.e. flank the target DNA sequence.
  • This DNA fragment can be prepared by PCR amplification of the selectable marker gene using as primers oligonucleotides that hybridize to the ends of the marker gene and that include the genomic regions that can recombine with the yeast genome.
  • the linear DNA fragment can be efficiently transformed into yeast and recombined into the genome resulting in gene replacement including with deletion of the target DNA sequence (as described in Methods in Enzymology, v 194, pp 281-301 (1991)).
  • promoter replacement methods may be used to exchange the endogenous transcriptional control elements allowing another means to modulate expression such as described in Mnaimneh et al. ((2004) Cell 118(1):31-44) and in the Examples herein.
  • the activity of target proteins in any yeast cell may be disrupted using random mutagenesis, which is followed by screening to identify strains with reduced activity of the target proteins such as e.g. a pyruvate decarboxylase.
  • the DNA sequence coding for the target proteins e.g. the pyruvate decarboxylase encoding region
  • any other region of the genome affecting expression of pyruvate decarboxylase activity need not even be known.
  • Methods for creating genetic mutations are common and well known in the art and may be applied to the exercise of creating mutants.
  • Commonly used random genetic modification methods include spontaneous mutagenesis, mutagenesis caused by mutator genes, chemical mutagenesis, irradiation with UV or X-rays, or transposon mutagenesis.
  • Chemical mutagenesis of yeast commonly involves treatment of yeast cells with one of the following DNA mutagens: ethyl methanesulfonate (EMS), nitrous acid, diethyl sulfate, or N-methyl-N'-nitro-N-nitroso-guanidine (MNNG).
  • EMS ethyl methanesulfonate
  • MNNG N-methyl-N'-nitro-N-nitroso-guanidine
  • Irradiation with ultraviolet (UV) light or X-rays can also be used to produce random mutagenesis in yeast cells.
  • the primary effect of mutagenesis by UV irradiation is the formation of pyrimidine dimers which disrupt the fidelity of DNA replication.
  • Protocols for UV-mutagenesis of yeast can be found in Spencer et al (Mutagenesis in Yeast, 1996, Yeast Protocols: Methods in Cell and Molecular Biology. Humana Press, Totowa, N.J.).
  • Introduction of a mutator phenotype can also be used to generate random chromosomal mutations in yeast.
  • Common mutator phenotypes can be obtained through disruption of one or more of the following genes: PMS1, MAGI, RAD18 or RAD51. Restoration of the non-mutator phenotype can be easily obtained by insertion of the wild type allele. Collections of modified cells produced from any of these or other known random mutagenesis processes may be screened for reduced activity of the target protein (
  • the host comprises a further genetic modification of at least one copy of a transcriptional regulator involved in glucose sensing.
  • S. cerevisiae strains in which the structural genes encoding pyruvate decarboxylase (PDC1, PDC5 and PDC6) are deleted are unable to grow in the presence of high glucose concentrations or under glucose-limited conditions without additional C 2 carbon sources such as ethanol or acetate - due to their inability to form cytosolic acetyl-CoA for e.g. fatty acid synthesis.
  • C 2 carbon sources is however preferably avoided for processes at industrial scale.
  • the transcriptional regulator is preferably encoded by the MTH1 gene or an orthologue thereof.
  • the genetic modification preferably is a genetic modification that increases the steady state level of the THi-encoded protein, by at least one of overexpressing the protein and inactivation of a phosphorylation site required for degradation of the transcriptional regulator.
  • the transcriptional regulator to be modified preferably has an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 79.
  • the genetic modification that inactivates the phosphorylation site preferably is an internal in- frame deletion of a segment comprising amino acid positions 57 - 131 of SEQ ID NO: 79, or a corresponding segment in an orthologue of SEQ ID NO: 79.
  • the endogenous cytosolic acetaldehyde dehydrogenase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of acetate from acetaldehyde.
  • Ald2p and Ald3p are cytosolic enzymes which use only NAD + as cofactor (EC 1.2.1.3). Both genes are induced in response to ethanol or stress and repressed by glucose.
  • Ald4p and Ald5p are mitochondrial, use NAD and NADP as co factors, and are K + dependent.
  • Ald4p, the major isoform is glucose repressed and ald4 mutants do not grow on ethanol, while Ald5p, the minor isoform, is constitutively expressed.
  • ALD6 encodes the Mg 2+ activated cytosolic enzyme, which uses NADP + as cofactor and is constitutively expressed (EC 1.2.1.4).
  • the cytosolic ALD6 gene product is the major enzyme responsible for catalyzing the oxidation of acetaldehyde to acetate in yeast.
  • the gene to be modified for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention is at least the S. cerevisiae ALD6 gene, encoding the amino acid sequence of SEQ ID NO: 5, or an orthologue thereof in another species. Therefore a gene to be modified for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 5. However, in other preferred cells the expression of one or more or all of the ALDl, ALD2, ALD3, ALD4, ALD5 and ALD6 genes or their corresponding orthologues is reduced or eliminated.
  • the specific cytosolic acetaldehyde dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, under aerobic or anaerobic conditions.
  • Methods for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
  • the endogenous alcohol dehydrogenase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of ethanol from acetaldehyde.
  • ADH1 to ADH5 there are five genes that encode alcohol dehydrogenases involved in ethanol metabolism, ADH1 to ADH5.
  • Adhlp, Adh3p, Adh4p, and Adh5p reduce acetaldehyde to ethanol during glucose fermentation, while Adh2p catalyzes the reverse reaction of oxidizing ethanol to acetaldehyde.
  • the cytosolic ADH1 gene product is the major enzyme responsible for catalyzing the reduction of acetaldehyde to ethanol with the concomitant regeneration of NAD + (EC 1.1.1.1).
  • a preferred gene to be modified for reducing or eliminating the specific ADH1 -encoded alcohol dehydrogenase activity in the cell of the invention is the S. cerevisiae ADH1 gene, encoding the amino acid sequence of SEQ ID NO: 6, or an orthologue thereof in another species. Therefore a gene to be modified for reducing or eliminating the specific ADH1 -encoded alcohol dehydrogenase activity in the cell of the invention, preferably is a gene encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 6.
  • preferred genes to be modified for reducing or eliminating the specific alcohol dehydrogenase activity in the cell of the invention are one or more of the S. cerevisiae ADH3, ADH4 and ADH5 genes or orthologues thereof in another species.
  • the S. cerevisiae ADH3, ADH4 and ADH5 genes or their orthologues may be modified as such, or in combination with the above modification of the ADH1 gene or its orthologue.
  • at least the S. cerevisiae ADH3 gene or its orthologue is modified for reducing or eliminating its specific activity in the cell of the invention, more preferably, in combination with the modification of at least one of the S. cerevisiae ADH1, ADH4 and ADH5 genes or their orthologues.
  • genes to be modified for reducing or eliminating the specific alcohol dehydrogenase activity in the cell of the invention preferably are genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to the amino acid sequences of the S. cerevisiae ADH3, ADH4 and ADH5 genes (with respectively Genbank accession no.'s CAA89229.1, CAA64131.1 and CAA85103.1 and SEQ ID NO's 87 - 89).
  • the specific (ADH1 -encoded or overall) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, under aerobic or anaerobic conditions.
  • the specific ( ⁇ DHJ-encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
  • the specific ( ⁇ 4ZXH ⁇ -encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
  • the specific ( ⁇ 4DH5-encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
  • Methods for reducing or eliminating the endogenous alcohol dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
  • the endogenous acetyl-CoA synthetase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of acetyl-CoA from acetate.
  • whether or not one or all of the endogenous acetyl-CoA synthetase genes are inactivated depends on the introduction of heterologous genes for the production of cytosolic acetyl-CoA; see 3.1, 3.2 and 3.3 below).
  • acetyl-CoA synthetase or acetate-CoA ligase (EC 6.2.1.1) is herein understood as an enzyme that catalyzes the formation of a new chemical bond between acetate and coenzyme A (CoA).
  • the acetyl- CoA synthetase activity can be reduced by modifying at least one gene encoding a acetyl-CoA synthetase.
  • one or both (all) of the ACS1 and ACS2 genes can be modified to reduce or eliminate their expression e.g. by disruption.
  • preferred genes to be modified for reducing or eliminating the specific acetyl-CoA synthetase activity in the cell of the invention are at least one of the S. cerevisiae ACS1 and ACS2 genes, encoding the amino acid sequence of SEQ ID NO's: 7 and 8, respectively, or orthologues thereof in another species.
  • genes to be modified for reducing the specific acetyl-CoA synthetase activity in the cell of the invention preferably are one or both of the genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to one or more of SEQ ID NO's: 7 and 8, respectively.
  • the specific acetyl-CoA synthetase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, under aerobic or anaerobic conditions.
  • Methods for reducing or eliminating the specific acetyl-CoA synthetase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
  • the activity of the product of the ACCI gene or an orthologue thereof is reduced in the host cell by genetically modifying the gene so as to avoid or reduce the formation of fatty acids, via the yeast native fatty acid forming pathway because this pathway would compete with the reversed ⁇ -oxidation pathway introduced in the host cell of the invention.
  • the S. cerevisiae ACCI gene encodes the acetyl-CoA carboxylase (EC 6.4.1.2) which catalyzes the carboxylation of cytosolic acetyl-CoA to form malonyl-CoA and regulates histone acetylation by regulating the availability of acetyl-CoA; required for de novo biosynthesis of long-chain fatty acids.
  • the S. cerevisiae ACCI gene or an orthologue thereof in another species is modified to reduce or eliminate activity of its gene product.
  • the S. cerevisiae ACCI gene encodes the amino acid sequence of SEQ ID NO: 9. Therefore a gene to be modified for reducing or eliminating the activity of the ACCI gene product or that of its orthologue in the cell of the invention, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 9.
  • the activity of the ACCI gene product can be reduced by adding the phospholipid precursors inositol and choline as ACCI is repressed in the presence of the phospholipid precursors, or by reducing the expression of the transcription factors Ino2p and Ino4p or by upregulating the negative ACCI regulator Opilp.
  • the activity of the ACCI gene product or that of its orthologue is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
  • Methods for reducing or eliminating acetyl-CoA carboxylase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
  • FAS2 is reduced or eliminated in the host cell so as to avoid or reduce (the initial steps of) fatty acid biosynthesis in which acetyl-CoA is consumed.
  • FAS1 and FAS2 encode the ⁇ - and a-subunits, respectively, of the fatty acid synthetase, which catalyzes the synthesis of long-chain saturated fatty acids.
  • the FAS1- encoded ⁇ -subunit contains acetyltransacylase, dehydratase, enoyl reductase, malonyl transacylase, and palmitoyl transacylase activities.
  • the ⁇ S ⁇ -encoded a-subunit contains the acyl-carrier protein domain and ⁇ -ketoacyl reductase, beta-ketoacyl synthase and self-pantetheinylation activities.
  • At least one the S. cerevisiae FAS1 preferably in a host cell of the invention, at least one the S. cerevisiae FAS1
  • FAS2 genes or their orthologues in another species are modified in order to avoid or reduce the initial steps of fatty acid biosynthesis in which acetyl-CoA is consumed.
  • S. cerevisiae FAS1 and FAS2 genes encode the amino acid sequences of SEQ ID NO's:
  • a gene to be modified for reducing or eliminating the initial steps of fatty acid biosynthesis in which acetyl-CoA is consumed preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 10 and 11.
  • fatty acid synthetase activity preferably is reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
  • Methods for reducing or eliminating the fatty acid synthetase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
  • the activity of the glyoxylate cycle is reduced or eliminated in the host cell.
  • the activity of the glyoxylate cycle is preferably at least reduced in the host cell of the invention because this cycle is another pathway competing (at least under aerobic conditions) for cytosolic acetyl-CoA. Its activity can be reduced or abolished by directly addressing the corresponding genes (CIT2, ICL1, MLS1 and MDH3) or by down-regulating their expression via down-regulation of the genes encoding one or more of the transcription factors HAP2, HAP3, HAP4 and HAP5.
  • At least one the S. cerevisiae CIT2, ICL1, MLS1, MDH3, HAP2, HAP3, HAP4 and HAP5 genes or their orthologues in another species are modified to reduce or eliminate activity of the glyoxylate cycle in the host cell.
  • the S. cerevisiae CIT2, ICL1, MLS1 and MDH3 genes respectively encode enzymes with citrate synthase, isocitrate lyase, malate synthase and (peroxisomal) NAD-dependent malate dehydrogenase activities, which enzymes have the amino acid sequences of SEQ ID NO's: 12, 13, 14, and 15, respectively.
  • a gene to be modified for reducing or eliminating activity of the glyoxylate cycle in the host cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 12, 13, 14, 15, 16, 17, 18, and 19.
  • the activity of the glyoxylate cycle is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
  • the specific pyruvate dehydrogenase activity is reduced or eliminated in the host cell.
  • Endogenous pyruvate dehydrogenase activity is located in the mitochondria in yeast and catalyzes oxidative decarboxylation of pyruvate to form acetyl-CoA.
  • Acetyl-CoA is used in the TCA cycle and in fatty acid biosynthesis.
  • the pyruvate dehydrogenase enzyme is one enzyme of a multi-enzyme pyruvate dehydrogenase complex.
  • Pyruvate dehydrogenase (EC 1.2.4.1) itself has alpha and beta subunits: encoded by the PDA1 and PDB1 genes, respectively, forming the El component.
  • the complex includes an E2 core which has dihydrolipoamide acetyltransferase activity (EC 2.3.1.12) and E3 which has dihydrolipoamide dehydrogenase activity (ECl .8.1.4).
  • E2 may be encoded by the LATI and E3 by LPDI genes.
  • An additional complex protein is encoded by the PDXl gene.
  • the pyruvate dehydrogenase complex may include the enzymes or subunits encoded by the PDAI, PDBI, LATI, LPDI, and PDXl genes. Any of the genes encoding pyruvate dehydrogenase complex enzymes of yeast may be modified to reduce pyruvate dehydrogenase activity in a yeast cell to prepare a strain of one embodiment of the invention.
  • At least one the S. cerevisiae PDAI, PDBI, LATI, LPDI, and PDXl genes or their orthologues in another species are modified to reduce or eliminate pyruvate dehydrogenase activity in the host cell.
  • the S. cerevisiae PDAI, PDBI, LATI, LPDI, and PDXl genes have the amino acid sequences of SEQ ID NO's: 20, 21, 22, 23, and 24, respectively.
  • a gene to be modified for reducing or eliminating pyruvate dehydrogenase activity in the host cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 20, 21, 22, 23, and 24.
  • the pyruvate dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
  • the activity of mitochondrial pyruvate carriers is reduced or eliminated in the host cell in order to reduce or to avoid loss of pyruvate in the citric acid cycle.
  • one or more of the S. cerevisiae MPCl, YIA6 and YEA6 genes is genetically modified, so as to reduce or eliminate the activity of mitochondrial pyruvate carriers in the cell.
  • MPCl encodes a highly conserved subunit of the mitochondrial pyruvate carrier; a mitochondrial inner membrane complex comprised of Fmp37p/Mpclp and either Mpc2p or Fmp43p/Mpc3p mediates mitochondrial pyruvate uptake.
  • YIA6 and YEA6 are members of the mitochondrial carrier subfamily and encode for a mitochondrial NAD + transporter, involved in the transport of NAD + and pyruvate into the mitochondria.
  • At least one the S. cerevisiae MPCl, YIA6 and YEA6 genes or their orthologues in another species are modified to reduce or eliminate the activity of mitochondrial pyruvate carriers in the cell.
  • the S. cerevisiae MPCl, YIA6 and YEA6 genes have the amino acid sequences of SEQ ID NO's: 25, 26 and 27, respectively.
  • a gene to be modified for reducing or eliminating the activity of mitochondrial pyruvate carriers in the cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 25, 26 and 27.
  • the activity of mitochondrial pyruvate carriers is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
  • the host cell of the invention is genetically modified so as to reduce or eliminate transport of acetyl-CoA from cytosol into mitochondria. This is preferably achieved by reducing or eliminating the activity of the carnitine shuttle by genetically modifying at least one of the S. cerevisiae YAT1, YAT2 and CRC1 genes or their orthologue in another species.
  • YAT1 encodes an outer mitochondrial carnitine acetyltransferase, minor ethanol- inducible enzyme involved in transport of activated acyl groups from the cytoplasm into the mitochondrial matrix.
  • YAT2 encodes a carnitine acetyltransferase; has similarity to Yatlp, which is a carnitine acetyltransferase associated with the mitochondrial outer membrane.
  • CRC1 encodes a mitochondrial inner membrane carnitine transporter, required for carnitine-dependent transport of acetyl-CoA from peroxisomes to mitochondria during fatty acid ⁇ -oxidation.
  • at least one the S. cerevisiae YAT1, YAT2 and CRC1 genes or their orthologues in another species are modified to reduce or eliminate transport of acetyl-CoA from cytosol into mitochondria in the cell via the carnitine shuttle.
  • the S. cerevisiae YAT1, YAT2 and CRC1 genes have the amino acid sequences of SEQ ID NO's: 28, 29, and 30, respectively.
  • a gene to be modified for reducing or eliminating transport of acetyl-CoA from cytosol into mitochondria in the cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 28, 29, and 30.
  • the transport of acetyl-CoA from cytosol into mitochondria in the cell is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
  • Methods for reducing or eliminating transport of acetyl-CoA from cytosol into mitochondria in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
  • the formation of glycerol as by-product is prevented or reduced by genetically modifying a plasma membrane channel involved in the efflux of glycerol from the host cell so as to reduce or eliminate its activity.
  • Reduction of glycerol efflux from the cell leads to a decreased production of glycerol by feed-back regulation as glycerol accumulates within the cells, thereby reducing the carbon flux towards glycerol biosynthesis.
  • the FSP1 gene encodes a aquaglyceroporin involved in efflux of glycerol.
  • the FSP1 gene encoded aquaglyceroporin is a plasma membrane (glycerol) channel and a member of major intrinsic protein (MIP) family.
  • the S. cerevisiae FSP1 gene is genetically modified to reduce or eliminate the efflux of glycerol from the cell.
  • the S. cerevisiae FSP1 gene has the amino acid sequence of SEQ ID NO: 31, respectively. Therefore a gene to be modified for reducing or eliminating the activity of the plasma membrane channel involved in the efflux of glycerol from the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 31.
  • the efflux of glycerol from the cell is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
  • the host cell is modified to de-repress catabolite (glucose) repressed genes by modification or inactivation of at least one of the endogenous SNF1 and MIG1 genes, or their orthologues.
  • the host cell preferably provides acetyl-CoA to feed into and drive the ⁇ - oxidation cycle in the reverse, i.e. biosynthetic direction.
  • the acetyl-CoA is preferably provided in the cytosol of the host cell through metabolic conversion from pyruvate. In microbes, several routes occur for converting pyruvate into acetyl-CoA.
  • the host cells of the invention preferably at least comprise one of the following routes for converting pyruvate into acetyl-CoA.
  • Yeast has an endogenous pyruvate dehydrogenase.
  • this enzyme complex is very slow and provides mitochondrial acetyl-CoA.
  • heterologous pyruvate oxidoreductase or dehydrogenase is available for expression in the host cells of the invention, including enzymes which use NAD + , NADP + , ferredoxin or flavin as co-factors (EC 1.2.4.1, EC 1.2.1.51, EC 1.2.7.1).
  • the heterologous pyruvate dehydrogenase expressed in the host cell uses the same co-factor as the co-factor that is used by the acyl-CoA dehydrogenase / transenoyl-CoA reductase (see 4.4 herein below).
  • Suitable heterologous pyruvate dehydrogenases for expression in the host cells of the invention may be obtained from E. coli (aceE, aceF, and lpdA), Zymomonas mobilis (pdhA[alpha], pdhA[beta], pdhB, and lpd), S. aureus (pdhA, pdhB, pdhC, and lpd), Bacillus subtilis, Corymb acterium glutamicum, or Pseudomonas aeruginosa US20100062505 (US20100248233: NADP+ dependent enzyme is oxygen sensitive and is large multimeric enzyme.
  • PDH-complex of Enterococcus faecalis is active under anoxic conditions (US20100062505).
  • the yeast native PDH pyruvate dehydrogenase complex which uses NADH as co factor and which includes the enzymes or subunits encoded by the PDA1, PDB1, LAT1, LPD I, and PDX1 genes could also be used, when overexpressed in the cytosol, by deletion or inactivation of the mitochondrial targeting signals of each of the subunits and using promoters described in 1.2 above.
  • Preferred pyruvate dehydrogenases are (acetyl-transferring) enzymes which use
  • NADH as co-factor (EC 1.2.4.1).
  • Nucleotide sequences encoding such enzymes can be derived e.g. from Enterococcus faecalis, Arabidopsis thaliana, Bos taurus, Coryneb acterium glutamicum, Escherichia coli, Homo sapiens, Zymomonas mobilis, Pseudomonas aeruginosa, Saccharomyces cerevisiae and Bacillus subtilis.
  • Another route for converting pyruvate into acetyl-CoA that can be used in the host cells of the invention is the direct conversion of cytosolic acetaldehyde (produced from pyruvate by pyruvate decarboxylase activity in the cytosol) to acetyl-CoA by introduction of a heterologous acetylating (NAD + -dependent) acetaldehyde dehydrogenase (E.C. 1.2.1.10).
  • cytosolic acetaldehyde produced from pyruvate by pyruvate decarboxylase activity in the cytosol
  • NAD + -dependent heterologous acetylating
  • An acetylating acetaldehyde dehydrogenases is also referred to as (CoA-acetylating) acetaldehyde :NAD -oxidoreductase or an acetyl-CoA reductase.
  • the conversion of acetaldehyde into acetyl-CoA by the acetylating acetaldehyde dehydrogenase is reversible and runs in the direction of acetyl-CoA when acetaldehyde accumulates in the cytosol. Such an accumulation can e.g.
  • ADH1 alcohol dehydrogenase
  • ALD6 acetaldehyde dehydrogenase
  • the heterologous acetaldehyde dehydrogenases for expression in the host cell of the invention preferably is a mono functional enzyme having only acetaldehyde dehydrogenase activity (i.e. an enzyme only having the ability to oxidize acetaldehyde into acetyl-CoA), such as e.g. the enzyme encoded by the E. coli mhpF gene, as opposed bifunctional enzymes with both acetaldehyde dehydrogenase and alcohol dehydrogenase activities, such as e.g. the bifunctional enzyme encoded by the E. coli adhE gene.
  • a suitable heterologous gene for expressing a mono functional enzyme having only acetaldehyde dehydrogenase activity is e.g. the E. coli mhpF gene.
  • a suitable exogenous gene coding for a mono functional enzyme with acetaldehyde dehydrogenase activity therefore comprises a nucleotide sequence coding for an amino acid sequence with at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 32 (the sequence of the E. coli mhpF gene).
  • Suitable examples of prokaryotes comprising mono functional enzymes with acetaldehyde dehydrogenase activity are provided in Table 1.
  • amino acid sequences of these mono functional enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding mono functional enzyme such as e.g. coding sequence of the E. coli mhpF gene codon optimized for expression in S. cerevisiae as depicted in SEQ ID NO's: 33 or 83.
  • a further route for converting pyruvate into acetyl-CoA that can be used in the host cells of the invention is the direct conversion of pyruvate into acetyl-CoA by introduction into the host cell of expression of a heterologous pyruvate formate lyase.
  • a pyruvate formate lyase is an enzyme with the ability to convert pyruvate and coenzyme-A into formate and acetyl-CoA catalyses the reaction (EC 2.3.1.54):
  • CoA coenzyme A
  • Such an enzyme is herein understood as an enzyme having pyruvate formate lyase activity and is referred to as a pyruvate formate lyase (PFL) or formate C- acetyltransferase .
  • a suitable heterologous gene coding for an enzyme with pyruvate formate lyase activity is e.g. a prokaryotic pyruvate formate lyase, such as the pyruvate formate lyase from E. coli.
  • the E. coli pyruvate formate lyase is a dimer of PflB (encoded by pflB), whose maturation requires the activating enzyme PflA (encoded by pflA), radical S- adenosylmethionine, and a single electron donor, which in the case of E. coli is flavodoxin (Buis and Broderick, 2005, Arch. Biochem. Biophys.
  • a suitable heterologous gene coding for an enzyme with pyruvate formate lyase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 34 (the amino acid sequence of the E. coli PflB).
  • Suitable examples of organisms comprising an enzyme with pyruvate formate lyase activity are provided in Table 2. Further examples of such organisms are listed by Lehtio and Goldman (2004, Prot. Engin. Design & Selection, 17:545-552). The amino acid sequences of these enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding enzyme with pyruvate formate lyase activity (see e.g. SEQ ID NO: 35 depicting the coding sequence of the E. coli pflB gene optimized for expression in S. cerevisiae).
  • the host cell of the invention further preferably comprises a heterologous gene coding for the PflA activating enzyme for activation of the pyruvate formate lyase.
  • the pyruvate formate lyase activating enzyme is herein understood as an enzyme that catalyses the reaction:
  • the heterologous gene coding for the pyruvate formate lyase activating enzyme preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 36.
  • Suitable examples of organisms comprising an enzyme with pyruvate formate lyase activity are provided in Table 3.
  • amino acid sequences of these enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding enzyme with pyruvate formate lyase activity (see e.g. SEQ ID NO: 37, depicting the coding sequence of the E. coli pflA gene optimized for expression in S. cerevisiae).
  • the heterologous genes coding for the enzyme with pyruvate formate lyase activity and the pyruvate formate lyase activating enzyme are from the same donor organism, i.e. be homologous to each other.
  • the exogenous genes coding for the enzyme with pyruvate formate lyase activity and the pyruvate formate lyase activating enzyme may also be from different donor organisms, i.e. be heterologous to each other.
  • a preferred host cell expressing pyruvate formate lyase activity further comprises a genetic modification that increases the specific NAD -dependent formate dehydrogenase activity in the cell to dispose of the potentially harmful formate that is produced by the pyruvate formate lyase.
  • a NAD + -dependent formate dehydrogenase is herein understood as an enzyme that catalyses the reaction: formate + NAD + ⁇ C0 2 + NADH + H + (EC 1.2.1.2).
  • a preferred gene encoding such a formate dehydrogenase whose activity is to be increased in the cell of the invention expressing heterologous pyruvate formate lyase activity is at least one of the endogenous S. cerevisiae FDH1 and FDH2 genes, or their orthologues in another species.
  • the S. cerevisiae FDH1 is described by van den Berg and Steensma (1997, Yeast 13:551-559) and the S. cerevisiae FDH2 is described by Overkamp et al. (2002, Yeast 19:509-520).
  • a gene encoding a formate dehydrogenase whose activity is to be increased in the cell of the invention preferably is a gene encoding a formate dehydrogenase having an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 38 and 39.
  • a heterologous formate dehydrogenase gene may be introduced into the cell in order to increase specific NAD -dependent formate dehydrogenase activity in the cell, such as e.g. the FDH1 gene from Candida boidinii.
  • the specific formate dehydrogenase activity is preferably increased by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to a strain which is genetically identical except for the genetic modification causing the reduction in specific activity, preferably under anaerobic conditions.
  • Formate dehydrogenase activity may be determined as described by Overkamp et al. (2002, supra).
  • Formate dehydrogenase activity is decreased in the cell of the invention.
  • Formate dehydrogenase activity is decreased in the cell by a genetic modification that reduces or eliminates expression of the above-defined formate dehydrogenase genes, using methods described in 2.1 above.
  • Another preferred host cell expressing pyruvate formate lyase activity comprises a further genetic modification that reduces or eliminates endogenous pyruvate decarboxylase activity as described in 2.1 above.
  • Conversion of pyruvate to acetyl-CoA via the "PDH-bypass" route by, optionally, overexpression of pyruvate decarboxylase (PDC1, PDC5 and/or PDC6) and acetaldehyde dehydrogenase (ALD6) and acetyl-CoA synthetase (ACSl or ACS2 or both) and optional reduction ethanol production by reduction or elimination of expression of an alcohol dehydrogenase encoded by at least one of ADH1, -3, -4 and -5 or their orthologues in other species.
  • PDC1 pyruvate decarboxylase
  • ALD6 acetaldehyde dehydrogenase
  • ACSl or ACS2 or both optional reduction ethanol production by reduction or elimination of expression of an alcohol dehydrogenase encoded by at least one of ADH1, -3, -4 and -5 or their orthologues in other species.
  • pyruvate decarboxylase acetyl-CoA synthetase and acetaldehyde dehydrogenase genes from other fungal and bacterial species can be expressed for the modulation of this pathway.
  • a variety of organisms could serve as sources for (nucleotide sequences coding for) these enzymes, including, but not limited to, Saccharomyces sp., including S. cerevisiae mutants and S. uvarum, Kluyveromyces, including K. thermotolerans, K. lactis, and K. mandanus, Pichia, Hansenula, including H. polymorpha, Candidia, Trichosporon, Yamadazyma, including Y.
  • pyruvate decarboxylase examples include those from Saccharomyces bay anus (1PYD), Candida glabrata, K. lactis (KIPDCl), or Aspergillus nidulans (PdcA), and acetyl-CoA synthetase from Candida albicans, Neurospora crassa, A. nidulans, or K.
  • prokaryotic enzymes include, but are not limited to, E. coli, Z. mobilis, Bacillus sp., Clostridium sp., Pseudomonas sp., Lactococcus sp., Enterobacter sp. and Salmonella sp. Further enhancement of this pathway can be obtained through engineering of these enzymes for enhanced activity by site-directed mutagenesis and other evolution methods (which include techniques known to those of skill in the art).
  • the acetyl-CoA synthetase that is expressed in the cell of the invention is a (heterologous) ADP-forming acetyl-CoA synthetase (EC 6.2.1.13), i.e. an acetyl-CoA synthetase which catalyzes the reaction:
  • Such an ADP-forming acetyl-CoA synthetase only consumes one ATP molecule for each acetyl- Co A synthesized, instead of two ATP molecules as is done by the native yeast enzyme which hydrolyses ATP to AMP and pyrophosphate.
  • the use of an ADP-forming acetyl-CoA synthetase thus avoids loss of energy by the formation of AMP + pyrophosphate.
  • Examples of ADP-forming acetyl-CoA synthetases include those of Salmonella enterica, P. aeruginosa, Pyrococcus furiosus, Archaeoglobus fulgidus and Pyrobaculum islandicum.
  • a preferred ADP-forming acetyl-CoA synthetase for expression in the cell of the invention is a variant of the Salmonella enterica acetyl-CoA synthetase (acssE), which acssE contains a point mutation (L641P) that prevents the enzyme from being inhibited by acetylation (Shiba et al. 2007; see SEQ ID NO. 40).
  • a preferred ADP-forming acetyl-CoA synthetase that is expressed in the cell is an ADP-forming acetyl-CoA synthetase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 40.
  • ADP-forming acetyl-CoA synthetase further has a mutation that prevents the enzyme from being inhibited by acetylation, such as a point mutation in a position corresponding to position 641 in SEQ ID NO: 40 in an alignment with SEQ ID NO: 40, preferably the point mutation is a mutation to a proline.
  • a codon-optimized sequence is used for expression of the ADP-forming acetyl-CoA synthetase, such as SEQ ID NO: 85, a sequence encoding SEQ ID NO: 40 optimized for expression in S. cerevisiae.
  • a heterologous acetaldehyde dehydrogenase is expressed in the cell which uses NAD + as co factor (instead of NADP + as the native yeast enzyme Ald6p does).
  • NAD + as co factor
  • a NAD + -dependent aldehyde dehydrogenase is expressed (optionally in combination with the inactivation of the endogenous yeast NADP + -dependent ALD6).
  • a suitable NAD + -dependent aldehyde dehydrogenase is e.g. an enzyme encoded by the aid gene of Pseudomonas aeruginosa, or an orthologue thereof.
  • a preferred NAD + -dependent aldehyde dehydrogenase that is expressed in the cell is an aldehyde dehydrogenase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 41.
  • a codon-optimized sequence is used for expression of the NAD + -dependent aldehyde dehydrogenase, such as SEQ ID NO: 84, a sequence encoding the P. aeruginosa aid optimized for expression in S. cerevisiae.
  • the host cell of the invention expresses enzymes of the fatty acid ⁇ -oxidation cycle.
  • the term "enzymes of the fatty acid ⁇ -oxidation cycle" are understood to comprise one or more or all enzymes having at least the following activities:
  • acetoacetyl-CoA an enzyme that catalyses the synthesis of acetoacetyl-CoA (either directly from two acetyl-CoA molecules or indirectly via a malonyl-CoA molecule and an acetyl- CoA molecule, resp. an acetoacetyl-CoA thiolases and an acetoacetyl-CoA synthase) and/or that catalyses the synthesis of ⁇ -ketoacyl-CoA from acetyl-CoA and a higher acyl-CoA (3-ketoacyl-CoA thiolases) as defined in 4.1 and 4.5;
  • the at least one or all of the enzymes of fatty acid ⁇ -oxidation cycle are preferably expressed in the absence of fatty acids and in the presence of a non- fatty acid carbon source.
  • the at least one or all enzymes do not require the presence of fatty acids in the growth medium for expression and, preferably, the expression of the at least one or all enzymes is insensitive to catabolite (glucose) repression, i.e. the enzymes are expressed in the presence of source of glucose.
  • the at least one or all enzymes are expressed at least under oxic (aerobic) and preferably also under anoxic (anaerobic) conditions. Examples of suitable promoters for the expressing the at least one or all enzymes are given in 1.2 above herein.
  • the enzymes of the fatty acid ⁇ -oxidation cycle are expressed in the cytosol of the eukaryotic host cell.
  • the enzymes of the fatty acid ⁇ -oxidation cycle are present in peroxisomes and/or in mitochondria.
  • the at least one or all of the enzymes of fatty acid ⁇ - oxidation cycle are preferably expressed in the cytosol of the host cell. Therefore, preferably, the ⁇ -oxidation enzymes are expressed in the cell without any targeting signal, e.g. for entry into peroxisomes or mitochondria such peroxisomal targeting signals (PTS-1 or -2) or mitochondrial targeting signals.
  • PTS-1 or -2 peroxisomal targeting signals
  • Nucleotide sequences coding for ⁇ -oxidation enzymes originating from eukaryotes are therefore preferably modified so as to delete or inactivated the targeting signals on the enzyme.
  • prokaryotic ⁇ -oxidation enzymes can be used that do not have any (cryptic) targeting signals.
  • expression of ⁇ -oxidation enzymes in the absence of inducing substrates is effected by de-regulation of transcription factors involved in ⁇ - oxidation (ADR1, OAF I, PIP2) thus causing overexpression of yeast's endogenous ⁇ - oxidation enzymes (POT1, FOX2, POX1), which preferably have been modified to delete or inactivate their peroxisomal targeting signals (PTS-1 or -2).
  • ADR1, OAF I, PIP2 transcription factors involved in ⁇ - oxidation
  • POT1, FOX2, POX1 yeast's endogenous ⁇ - oxidation enzymes
  • the invention relates to enzymes that condense acetyl-CoA either with another acetyl-CoA or with a higher acyl-CoA into a ⁇ -ketoacyl-CoA.
  • thiolases are known as acetoacetyl-CoA thiolases (EC 2.3.1.9) or 3-ketoacyl- CoA thiolases (EC 2.3.1.16), respectively.
  • Yeast own thiolase (POT1) has no isoenzymes, therefore the enzyme must be able to metabolize substrates of all chain- length (Mursula 2002).
  • the yeast own enzyme could be used or as an alternative a heterologous enzyme could be used in case the yeasts enzyme exhibits poor conversion rate towards ⁇ -ketoacyl-CoA (acetoacetyl-CoA in case of C 4 ).
  • acetoacetyl-CoA endogenous cytosolic ERG10 could be used as thiolase (as acetoacetyl-CoA thiolase for short chain products).
  • the yeast POT I should be expressed without a functional N-terminal peroxisomal targeting sequence (PTS-2, peroxisome-targeting signal sequence) to enable cytosolic expression.
  • an N-terminally truncated or mutated POT1 is expressed, as e.g. described in Glover et al. (1994, J. Biol. Chem. 269: 7558-7563) (SEQ ID NO: 42 depicts the POT1 encoded S. cerevisiae thiolase lacking the N-terminal 16 amino acid PTS-2).
  • ketoacyl-thiolases occur within the mitochondria and within the peroxisomes. They differ with respect to their substrate and stereospecifity.
  • the mitochondria contain two short- and medium chain specific 3-ketoacyl-CoA thiolases. One is specific for acetoacetyl-CoA and 2-methylacetoacetyl-CoA and the other for substrates ranging from C 6 to C 16 (Eaton et al, 1996, Biochem. J. 320:345-357).
  • peroxisomes multiple enzyme iso forms exist (some inducible by peroxisome proliferators).
  • Suitable nucleotide sequences coding for homologous or heterologous thiolases are available from a number of sources, for example, Escherichia coli (GenBank No.'s: NP-416728, NC-000913); Clostridium acetobutylicum (GenBank Nos: NP-349476.1; NC-003030; NP-149242; NC-001988), Bacillus subtilis (GenBank Nos: NP-390297; NC-000964), and Saccharomyces cerevisiae (GenBank Nos: ERG10: NP-015297; POT1 : EEU05467.1), C. acetobutylicum sp.
  • Clostridium perfringens sp. e.g., protein ID ABG86544.1, ABG83108.1
  • thermosaccharolyticum e.g., protein ID CAJ67900.1 or ZP-01231975.1
  • Thermoanaerobacterium thermosaccharolyticum e.g., protein ID CAB07500.1
  • Thermoanaerobacter tengcongensis e.g., AAM23825.1
  • Carboxydothermus hydrogenoformans e.g., protein ID ABB13995.1
  • Desulfotomaculum reducens MI-1 e.g., protein ID EAR45123.1
  • Candida tropicalis e.g., protein ID BAA02716.1 or BAA02715.1
  • Saccharomyces cerevisiae e.g., protein ID AAA62378.1 or CAA30788.1
  • Bacillus sp. Megasphaera elsdenii
  • Butryivibrio fibrisolvens e.g., Megasphaera elsdenii, and Butryivibrio fibrisolvens.
  • S. cerevisiae thiolases could also be active in a heterologously expressed pathway (ScERGlO, POT1) (see e.g. US20100062505). Further suitable thiolase coding sequences are listed in US2008182308.
  • a suitable gene coding for an enzyme with short chain specific thiolase activity for expression in a cell according to the invention is preferably derived from S. cerevisiae (ERG 10), E. coli (atoB), Ralstonia eutrophus (PhaA) and orthologues thereof comprising a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 43, 44 and 80 respectively.
  • a suitable gene coding for an enzyme with broad chain-length specificity thiolase activity for expression in a cell according to the invention is preferably derive from S. cerevisiae (POT1) or E. coli (FadA) and comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 42 or 45, respectively.
  • thiolases are encoded by the PhaA gene from Ralstonia eutrophus (Zhang et al. 2011, Curr. Op. Biotechnol, 22:775-783; Bond- Watts et al, 2011, Nat Chem Biol, 7:222-227) or the E. coli yqeF gene, which has an affinity for short chain substrates (Dellomonaco et al, 2011, supra).
  • PhaA PhaA gene from Ralstonia eutrophus
  • Curr. Op. Biotechnol, 22:775-783 Bond- Watts et al, 2011, Nat Chem Biol, 7:222-227
  • E. coli yqeF gene which has an affinity for short chain substrates (Dellomonaco et al, 2011, supra).
  • the invention relates to enzymes that reduce a ⁇ -ketoacyl- CoA into a trans-P-hydroxyacyl-CoA.
  • Yeast's own hydroxyacyl-CoA dehydrogenase (FOX2) is a multifunctional peroxisomal enzyme catalyzing the D-specific hydroxyacyl-CoA dehydrogenase and D-specific enoyl-CoA hydratase activity.
  • FOX2 catalyzes the same D-specific reactions as the mammalian MFE-2.
  • the yeast FOX2 encoded hydroxyacyl-CoA dehydrogenase has no isoenzymes, therefore the enzyme must be able to metabolize substrates of a broad range of chain- lengths (Mursula, A., 2002, "A3-A2-Enoyl-CoA Isomerase from the yeast Saccharomyces cerevisiae. Molecular and structural characterization". Academic Dissertation, Faculty of Science, University of Oulu, FI,). Therefore, the yeast endogenous FOX2 encoded enzyme could be used or as an alternative a heterologous enzyme could be used in case the yeasts enzyme exhibits poor conversion rate towards trans-P-hydroxyacyl-CoA.
  • the expression of the yeast FOX2 encoded enzyme is relocated from the peroxisome to the cytosol by expression of the enzyme without a functional peroxisome-targeting signal (PTS-1), i.e. the C-terminal tripeptide having the sequence SKL.
  • PTS-1 peroxisome-targeting signal
  • an C-terminally truncated or mutated FOX-2 encoded enzyme e.g. comprising an amino acid sequence as depicted in SEQ ID NO: 46 (the S. cerevisiae FOX2 lacking the C-terminal 3 amino acid PTS-1), or an orthologue thereof, is expressed in a cell of the invention.
  • Heterologous hydroxyacyl-CoA dehydrogenases may be reduced NADH- dependent, with a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3- hydroxyacyyl-CoA and are classified as E.C. 1.1.1.35 and E.C. 1.1.1.30, respectively.
  • 3-hydroxyacyyl-CoA dehydrogenases may be reduced NADPH- dependent, with a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3- hydroxyacyyl-CoA and are classified as E.C. 1.1.1.157 and E.C. 1.1.1.36, respectively.
  • Suitable (nucleotide sequences coding for) heterologous 3-hydroxybutyryl-CoA dehydrogenase enzymes are available from a number of sources, for example, Clostridium acetobutylicum (GenBank NOs: NP-349314; NC-003030), B. subtilis (GenBank NOs: AAB09614; U29084), Ralstonia eutropha (GenBank NOs: YP- 294481; NC-007347), and Alcaligenes eutrophus (GenBank NOs: AAA21973; J04987). Suitable genes encoding 3-hydroxybutyryl-CoA dehydrogenases are also listed in US2008182308.
  • nucleotide sequences coding for are enzymes homologous to the Clostridium acetobutylicum genes include, but are not limited to: Clostridium kluyveri, which expresses two distinct forms of this enzyme (Miller et al, J. Bacteriol. 138:99-104, 1979), and Butyrivibrio fibrisolvens, which contains a bhbd gene which is organized within the same locus of the rest of its butyrate pathway (Asanuma et al, Current Microbiology 51 :91-94, 2005; Asanuma at al, Current Microbiology 47:203-207, 2003).
  • SCAD short chain acyl-CoA dehydrogenase
  • Clostridium tetani E88 (NP-782952.1), Clostridium perfringens SM101 (YP-699558.1), Clostridium perfringens str. 13 (NP-563213.1), Clostridium saccharobutylicum (AAA23208.1), Clostridium beijerinckii NCIMB 8052 (ZP- 00910128.1), Clostridium beijerinckii (AF494018-5), and in Thermoanaerobacter tengcongensis MB4 (NP-622220.1), Thermoanaerobacterium thermosaccharolyticum (CAB04792.1), Alkaliphilus metalliredigenes QYMF (ZP-00802337.1) and E. coli (see e.g. US20100062505).
  • a suitable gene for expression in a cell according to the invention and coding for an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity with higher specificity for short chain substrates preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 47 (Hbd; C. acetobutylicum) and 48 (Hbd; C beijerinckii).
  • Suitable gene for expression in a cell according to the invention and coding for an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity with a broader chain- length specificity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 49 (fadB; E. coli) or 46 (FOX2; S. cerevisiae).
  • the invention relates to enzymes that dehydrate a trans- ⁇ - hydroxyacyl-CoA into a trans-A2-enoyl-CoA.
  • yeast's own enoyl-CoA hydratase (FOX2) is a multifunctional enzyme that has both D-specific hydroxyacyl-CoA dehydrogenase and D-specific enoyl-CoA hydratase activities and it has a broad chain-length specificity.
  • the E. coli FadB gene encodes a bifunctional enzyme having both dehydrogenase and hydratase activities as well as a broad chain-length specificity. Therefore, for the production of longer chain products, i.e.
  • a enoyl-CoA hydratase is expressed in the cell of the invention that is part of a multifunctional enzyme that also has hydroxyacyl-CoA dehydrogenase activity, such as described above in 4.2.
  • a preferred nucleotide sequence coding for a multifunctional enzyme having hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities and having a broader chain-length specificity is a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 49 (FadB; E. coli) or 46 (FOX2; S. cerevisiae), whereby the latter is relocated to the cytosol by deleting or inactivating its peroxisomal targeting signal.
  • a separate heterologous enoyl- CoA hydratase or crotonase is expressed in the cell of the invention together with a separate 3-hydroxybutyryl-CoA dehydrogenase with short chain substrate specificity such as the Hbd enzymes from Clostridium having amino acid sequence identity with at least one of SEQ ID NO: 47 and 48, as defined above in 4.2.
  • Such heterologous enoyl-CoA hydratases may have a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3-hydroxyacyl-CoA and are classified as E.C. 4.2.1.17 and E.C. 4.2.1.55, respectively.
  • Suitable (nucleotide sequences coding for) enoyl-CoA hydratases are available from a number of sources, for example, E. coli (GenBank NOs: NP-415911; NC-000913), C. acetobutylicum (GenBank NOs: NP-349318; NC- 003030), B.
  • subtilis GenBank NOs: CAB13705; Z99113
  • Aeromonas caviae GenBank NOs: BAA21816; D88825
  • the crotonases or enoyl-CoA hydratases are enzymes that catalyze the reversible hydration of cis and trans enoyl-CoA substrates to the corresponding ⁇ -hydroxyacyl CoA derivatives.
  • this step of the butanoate metabolism is catalyzed by EC 4.2.1.55, encoded by the crt gene (GenBank protein accession AAA95967, Kanehisa, Novartis Found Symp.
  • a suitable gene coding for a separate heterologous enzyme with crotonase or enoyl-CoA hydratase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 50 (C. acetobutylicum crt) and 51 (C. beijerinckii crt).
  • Such genes include, but are not limited to, Clostridium tetani E88 (NP-782956.1), Clostridium perfringens SM101 (YP- 699562.1), Clostridium perfringens str.
  • Suitable genes are homologous genes from Fusobacterium nucleatum subsp. Vincentii (Q7P3U9-Q7P3U9_FUSNV), Clostridium difficile (P45361-CRT CLODI), Clostridium pasteurianum (P81357-CRT CLOPA), and Brucella melitensis (Q8YDG2-Q8YDG2 BRUME) (see e.g. US20100062505).
  • the invention relates to enzymes that reduce a trans-A2- enoyl-CoA into an acyl-CoA.
  • These enzymes may be either NADH- or NADPH- or flavoprotein dependent and are classified as E.C. 1.3.1.44, E.C. 1.3.1.38 or EC 1.3.8.1, respectively.
  • trans-2-enoyl-CoA reductase or "TER” are understood herein to refer to enzymes that are capable of catalyzing the conversion of trans-2-enoyl-CoA to acyl- CoA.
  • Acyl-CoA dehydrogenases or transenoyl-CoA reductases are available from a number of sources, for example, C. acetobutylicum (GenBank NOs: NP-347102); NC- 003030), Euglena gracilis (GenBank NOs: -AAW66853), AY741582), Streptomyces collinus (GenBank NOs: AAA92890; U37135), and Streptomyces coelicolor (GenBank NOs: CAA22721; AL939127). Further suitable genes are listed in e.g. US2008182308.
  • transenoyl-CoA reductases include, but are not limited to, the enzymes from Clostridium tetani E88 (NP-782955.1 or NP-781376.1), Clostridium perfringens str. 13 (NP-563216.1), Clostridium beijerinckii (AF494018-2), Clostridium beijerinckii NCIMB 8052 (ZP-00910125.1 or ZP-00909697.1), and Thermoanaerobacterium thermosaccharolyticum (CAB07496.1), Thermoanaerobacter tengcongensis MB4 (NP- 622217.1).
  • TER trans-2-enoyl-CoA reductase
  • BLAST BLAST
  • TER proteins include, but are not limited to Euglena spp. including, but not limited to, E. gracilis, Aeromonas spp. including, but not limited, to A. hydrophila, Psychromonas spp. including, but not limited to, P. ingrahamii, Photobacterium spp. including, but not limited, to P. profundum, Vibrio spp. including, but not limited, to V. angustum, V.
  • cholerae V alginolyticus, V parahaemolyticus, V vulnificus, V fischeri, V spectacularus, Shewanella spp. including, but not limited to, S. amazonensis, S. woodyi, S. frigidimarina, S. paeleana, S. baltica, S. denitrificans, Oceanospirillum spp., Xanthomonas spp. including, but not limited to, X oryzae, X campestris, Chromohalobacter spp. including, but not limited, to C. salexigens, Idiomarina spp. including, but not limited, to /.
  • baltica Pseudoalteromonas spp. including, but not limited to, P. atlantica, Alteromonas spp., Saccharophagus spp. including, but not limited to, S. degradans, S. marine gamma proteobacterium, S. alpha proteobacterium, Pseudomonas spp. including, but not limited to, P. aeruginosa, P. putida, P. fluorescens, Burkholderia spp. including, but not limited to, B. phytofirmans, B. cenocepacia, B. cepacia, B. ambifaria, B. vietnamensis, B. multivorans, B.
  • Methylbacillus spp. including, but not limited to, M. flageliatus, Stenotrophomonas spp. including, but not limited to, S. maltophilia, Congregibacter spp. including, but not limited to, C. litoralis, Serratia spp. including, but not limited to, S. proteamaculans, Marinomonas spp., Xytella spp. including, but not limited to, X fastidiosa, Reinekea spp., Colweffia spp. including, but not limited to, C. psychrerythraea, Yersinia spp. including, but not limited to, Y.
  • TER enzymes are chosen that use the same co-factor as the (heterologous) pyruvate dehydrogenase (see 3.1 above).
  • Suitable NADH-dependent enzymes are e.g. the TER enzymes from Treponema denticola (NP_971211; SEQ ID NO: 52) and Euglena gracilis (AAW66853; SEQ ID NO: 53), of which the TER encode by the gene from T. denticola is most preferred (Zhang et al 201 1 supra, Hu et al, 2013 Biochem J. 449(l):79-89).
  • a suitable gene coding for an enzyme with transenoyl-CoA reductase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 52 ( T. denticola) and 53 (E. gracilis).
  • acetoacetyl-CoA instead of or in addition to using the direct condensation of acetyl-CoA by a thiolase (see 4.1. above), an alternative route is used for generation acetoacetyl-CoA through the ATP-driven malonyl-CoA synthesis as described by Lan and Liao (2012, Proc. Natl. Acad. Sci. 109:6018-6023).
  • ATP is used to drive the thermodynamically unfavorable condensation of two acetyl-coA molecules to acetoacetyl-CoA.
  • the host cell expresses enzymes that catalyze ATP-driven malonyl-CoA synthesis and decarboxylative carbon chain elongation to drive the carbon flux into the formation of acetoacetyl-CoA, which then further undergoes the reverse ⁇ -oxidation to synthesize butyryl-CoA and/or subsequent higher acyl-CoA's.
  • the host cell therefore expresses or overexpresses an acetyl-CoA carboxylase (Acc), which synthesizes malonyl-CoA from acetyl-CoA, HCO 3 and ATP.
  • Acc acetyl-CoA carboxylase
  • a suitable acetyl-CoA carboxylase for expression in the cell of the invention is e.g. (overexpression of) the Saccharomyces cerevisiae ACC1 gene (DAA10557; SEQ ID NO 9) or the Homo sapiens ACC1 (Q13085; SEQ ID NO 54.
  • a preferred gene coding for an enzyme with acetyl-CoA carboxylase activity for expression in a cell of the invention preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO's: 9 and 54. It is therefore understood that in this embodiment, preferably, the endogenous acetyl-CoA carboxylase in the host cell is not reduced or eliminated (see 2.5 above).
  • the host further expresses an enzyme with acetoacetyl-CoA synthase activity, which catalyses the decarboxylative condensation of acetyl-CoA and malonyl-CoA to form acetoacetyl-CoA.
  • a suitable acetoacetyl-CoA synthase is e.g. the Streptomyces sp. CL190 nphT7 gene encoded acetyl-CoA:malonyl-CoA acyltransferase (AB540131 ; SEQ ID NO 55).
  • a preferred gene coding for an enzyme with acetoacetyl-CoA synthase activity for expression in a cell of the invention preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 55.
  • a thiolase with broad chain-length specificity preferably, in addition also a thiolase with long chain-length specificity (i.e. C 6 and longer), is expressed in accordance with 4.1 above,. 5.
  • the invention relates to termination enzymes, which are expressed in the cells of the invention to branch products off from the reverse ⁇ - oxidation cycle for the production of specific products, such as fatty acids, 1 -alcohols, ⁇ -ketoacids, ⁇ -ketoalcohols, ⁇ -hydroxy acids, 1,3-diols, trans-A 2 -fatty acids, alkenes, alkanes and derivatives thereof, whereby the chain-length specificity of the termination enzyme can determine the chain-length of the final product.
  • specific products such as fatty acids, 1 -alcohols, ⁇ -ketoacids, ⁇ -ketoalcohols, ⁇ -hydroxy acids, 1,3-diols, trans-A 2 -fatty acids, alkenes, alkanes and derivatives thereof, whereby the chain-length specificity of the termination enzyme can determine the chain-length of the final product.
  • the invention relates to enzymes that convert a ⁇ - ketoacyl-CoA into a desired product.
  • the invention relates to enzymes that catalyzes the formation of ⁇ -ketoalcohols from ⁇ -ketoacyl-CoA such as e.g. an alcohol- forming CoA thioester reductases, an aldehyde- forming CoA thioester reductases or an alcohol dehydrogenases.
  • ⁇ -ketoacyl-CoA such as e.g. an alcohol- forming CoA thioester reductases, an aldehyde- forming CoA thioester reductases or an alcohol dehydrogenases.
  • the invention relates to enzymes that catalyzes the formation of ⁇ -ketoacids from ⁇ -ketoacyl-CoA such as e.g. thioesterases or CoA thioester hydrolases.
  • a suitable enzyme for this purpose is e.g. the E. coli acyl-CoA thioesterase II tesB, which forms ⁇ -ketobutyric acid from ⁇ -ketobutyl-CoA.
  • the invention relates to enzymes that convert a trans- - hydroxyacyl-CoA into a desired product.
  • the invention relates to enzymes that catalyzes the formation of a 1,3-diol from trans ⁇ -hydroxyacyl-CoA, such as e.g. an alcohol- forming CoA thioester reductases, aldehyde- forming CoA thioester reductase or an alcohol dehydrogenases.
  • a 1,3-diol such as e.g. an alcohol- forming CoA thioester reductases, aldehyde- forming CoA thioester reductase or an alcohol dehydrogenases.
  • a 1,3-diol such as e.g.
  • the cell expresses an encoding NAD(P)H-dependent acetoacetyl-CoA reductase and at least one of a butyraldehyde dehydrogenase and an alcohol/aldehyde dehydrogenase (see e.g. Kataoka et al, 2012, J. Biosci. Bioeng. http://dx.doi.Org/10.1016/j.jbiosc.2012.l l .025).
  • a preferred NAD(P)H-dependent acetoacetyl-CoA reductase is the PhaB acetoacetyl-CoA reductase from Ralstonia eutropha or an orthologue thereof such as an acetoacetyl-CoA reductase having an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 81 (PhaB of Ralstonia eutropha).
  • a preferred butyraldehyde dehydrogenase is the bid butyraldehyde dehydrogenase from Clostridium saccharoperbutylacetonicum ATCC 27012 or an orthologue thereof such as a butyraldehyde dehydrogenase having an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 82 (bid of C. saccharoperbutylacetonicum).
  • a preferred alcohol/aldehyde dehydrogenase is the adhE NADH-dependent aldehyde/alcohol dehydrogenase from Clostridium acetobutylicum or an orthologue thereof, such as a dehydrogenase having an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 57 (adhE2 of C. acetobutylicum).
  • the invention relates to enzymes that catalyzes the formation of a ⁇ -hydroxyacid from trans-P-hydroxyacyl-CoA, such as e.g. an acyl-CoA thioesterase.
  • a suitable enzyme for production longer chain products is are e.g. the acyl-CoA thioesterase (EC 3.1.2.27) derived from Mus musculus (PTE-2, NM_133240) and expressed without a functional PTS-1 tripeptide, or an orthologue thereof. This enzymes converts 3-hydroxyhexadecanoyl-CoA into CoA and 3- hydroxyhexadecanoate.
  • a suitable enzyme for production of short chain products is e.g. the acyl-CoA thioesterase I (tesA) from E. coli or orthologues thereof, e.g. for the synthesis of ⁇ -hydroxybutyric acid.
  • a suitable gene coding for an enzyme with acyl-CoA thioesterase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 72 (Mus musculus PTE-2 without C-terminal PTS-1) or SEQ ID NO: 73 (E. coli tesA).
  • the invention relates to enzymes that convert an acyl-CoA into a desired product.
  • the invention relates to enzymes that catalyze the conversion of acyl-CoA to an aldehyde and/or an alcohol.
  • the enzyme catalyses the conversion into aldehydes or alcohols with (linear) chains longer than C 2 , preferably at least C 4 .
  • a preferred enzyme that catalyzes the conversion of acyl-CoA to an aldehyde is an enzyme that uses NADH or NADPH as co factor (EC 1.2.1.10 or EC 1.2.1.57). It is understood herein that in order to maintain a proper redox-balance either one of an NADH- or NADPH-dependent aldehyde dehydrogenases may be chosen in the host cell of the invention, depending on the co-factor dependencies of other enzymes expressed in the cell.
  • a suitable aldehyde dehydrogenases is e.g. encoded by the E.
  • coli mhpF gene (GenBank No CAA70751; SEQ ID NO: 32 encoded by the codon optimized SEQ ID NO's: 33 or 83) and orthologues thereof as defined in 3.2.
  • aldehyde dehydrogenases may be derived from Clostridium beijerinckii (GenBank NOs: AAD31841), AF157306 and C. acetobutylicum (GenBank NOs: NP- 149325), NC-001988). Further suitable genes are listed in US2008182308.
  • a preferred enzymes that catalyze the conversion of an aldehyde to a 1 -alcohol uses either NADH or NADPH as cofactor.
  • NADH or NADPH as cofactor.
  • either one of an NADH- or NADPH-dependent alcohol dehydrogenases may be chosen in the host cell of the invention, depending on the co-factor dependencies of other enzymes expressed in the cell.
  • Alcohol dehydrogenases are available from, for example, E. coli (fucO) (GenBank No YP_002927733; SEQ ID NO. 56), C.
  • acetobutylicum (GenBank NOs: NP-149325, NC- 001988; which enzyme possesses both aldehyde and alcohol dehydrogenase activity); NP-349891 , NC-003030; and NP-349892, NC-003030 and E. coli (GenBank NOs: NP- 417-484, NC-000913).
  • the AdhE2 of C. acetobutylicum may be less preferred because it is oxygen sensitive.
  • a suitable gene coding for an enzyme with NADH-dependent alcohol dehydrogenases activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 56 (E. coli fucO) or 57 (C. acetobutylicum adhE2).
  • Clostridium tetani E88 (NP-781989.1), Clostridium perfringens str. 13 (NP-563447.1), Clostridium perfringens ATCC 13124 (YP- 697219.1), Clostridium perfringens SM101 (YP-699787.1), Clostridium beijerinckii NCIMB 8052 (ZP-00910108.1), Clostridium acetobutylicum ATCC 824 (NP- 149199.1), Clostridium difficile 630 (CAJ69859.1), Clostridium difficile QCD-32g58 (ZP-01229976.1), and Clostridium thermocellum ATCC 27405 (ZP-00504828.1).
  • BDH I Two suitable n-butanol dehydrogenases from C. acetobutylicum (BDH I, BDH II) have been purified, and their genes (bdbA, bdhB) cloned.
  • GenBank accession for BDH I is AAA23206.1.
  • GenBank accession for BDH II is AAA23207.1.
  • BDH I utilizes NADPH as the cofactor, while BDH II utilizes NADH, which is more preferred.
  • Even more preferred at least for the production of n-butanol is adhE2 gene of C. acetobutylicum (GenBank accession #AF321779; SEQ ID NO: 57).
  • a preferred gene coding for an enzyme for the production of n-butanol comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 57.
  • Such homologues include, but are not limited to, Clostridium perfringens SM101 (YP-699787.1), Clostridium perfringens str. 13 (NP-563447.1), Clostridium perfringens ATCC 13124 (YP-697219.1), Clostridium tetani E88 (NP-781989.1), Clostridium beijerinckii NCIMB 8052 (ZP-00910108.1), Clostridium difficile QCD- 32g58 (ZP-01229976.1), Clostridium difficile 630 (CAJ69859.1), Clostridium acetobutylicum ATCC 824 (NP- 149325.1), and Clostridium thermocellum ATCC 27405 (ZP-00504828.1) (see e.g. US20100062505).
  • butanol dehydrogenases E.C. 1.1.1.1
  • NADPH-dependent butanol dehydrogenases E.C. 1.1.1.1
  • bifunctional NADH-dependent or NADPH-dependent aldehyde/alcohol dehydrogenases E.C. 1.1.1.1./1.2.1.10
  • butyryl-CoA converts butyryl-CoA to 1-butanol via butyraldehyde
  • fatty acyl-CoA reductases can be use as termination enzyme.
  • Fatty acyl-CoA reductases can be divided into two classes that differ with respect to the end-product synthesized, i.e. the aldehyde- and the alcohol- forming enzymes.
  • Aldehyde-generating FAR catalyze a two- electron reduction of activated fatty acids, so that fatty aldehydes are formed.
  • Such enzymes have been described in pea leaves, green algae and bacteria.
  • the fatty aldehydes can be further reduced to fatty alcohols by fatty aldehyde reductases or can be involved in the biosynthesis of hydrocarbons.
  • alcohol- forming FAR catalyze the reduction of activated fatty acids to fatty alcohols.
  • This four-electron reduction takes place in two steps. In the first step an aldehyde is formed, that is subsequently reduced to a fatty alcohol in the second step.
  • Proteins have been purified and genes encoding alcohol- forming FAR were identified in plants, mammals, insects, birds and protozoa. They usually require NADPH as electron donor but in certain organisms like Euglena gracilis NADPH can be substituted by NADH.
  • the FAR in Euglena gracilis uses 14:0, 16:0 and 18:0 as substrates and requires NADH as cofactor. Functional analysis of EgFAR in yeast indicated that it could effectively convert 14:0 and 16:0 fatty acids to their corresponding alcohols. Compared with other biochemically characterized FARs, EgFAR possesses a narrower substrate range, only using saturated fatty acids with 14 and 16 carbon chains as substrates with the preferred fatty acid being 14:0 when expressed in yeast. (Teerawanichpan and Qiu, 2010, Lipids, 45(3):263-73).
  • a preferred gene coding for a termination enzyme for the production of C 14 and/or C 16 alcohols comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 58.
  • FAR genes for expression in the cells of the invention for the production of longer chains alcohols and/or aldehydes are described by Hellenbrand et al. (2011, BMC Biochem. 12:64) and include e.g. the bird fatty acyl-CoA reductases: AdFARl JN638548, AmFARl NP 001 180219.1 , AtCER4 NP 567936.5, AtFARl NP 197642.1 , AtFAR4 NP 190040.3, AtFAR5 NP 190041.2, AtFAR6 AEE79553.1 , AtFAR8 NP l 90042.2, AtMS2 AEE75132.1 , BmFAR NP 001036967.1 , EgFAR ADI60057.1 , FAR1 NP OO 1026350.1 , FAR2 XP 417235.2, HsFARl NP l 15604.1 , HsFAR2 NP 060569.3, MmFARl NP
  • a further suitable termination enzyme for producing longer chain alcohols i.e.
  • C 6 , Cs, or Cio or longer is an iron-dependent, NAD + -dependent (long chain) aldehyde/alcohol dehydrogenase such as e.g. encoded by the E. coli yiaY gene.
  • a preferred gene coding for a termination enzyme for the production of longer chains alcohols comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 59.
  • the invention relates to the biosynthesis of fatty acids.
  • Preferred enzymes to be expressed in the cells of the invention for the biosynthesis of fatty acids are enzymes that catalyze the deacylation (hydrolysis) of acyl-CoA thioesters to fatty acids and CoA (EC 3.1.2.2) e.g.
  • an acyl-CoA thioesterase from Anas platyrhynchos, Arabidopsis thaliana, Bumilleriopsis filiformis, Candida rugosa, Cricetulus griseus, Eremosphaera viridis, Escherichia coli, Euglena gracilis, Homo sapiens, Mougeotia scalaris, Mus musculus, Mycobacterium phlei, Mycobacterium smegmatis, Oryctolagus cuniculus, Pseudomonas aeruginosa, Rattus norvegicus, Rhodotorula aurantiaca, Rhodobacter sphaeroides, Saccharomyces cerevisiae, Streptomyces coelicolor, Streptomyces venezuelae, and Sus scrofa.
  • a preferred enzyme is an enzyme that catalyzes the deacylation of long chain acyl-CoA thioesters to long chain fatty acids, i.e. fatty acid with a chain-length of C 6 , Cs, or Cio or longer.
  • a preferred gene coding for a termination enzyme for the production of longer chains fatty acids comprises a nucleotide sequence coding for an acyl-CoA thioesterase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 74 (hBACH; D88894) and SEQ ID NO: 75 (E. coli fadM; NP_414977).
  • the invention relates to the biosynthesis of alkenes.
  • a preferred enzyme to be expressed in the cells of the invention for the biosynthesis of alkenes from acyl-CoA is an olefin synthase.
  • a suitable olefin synthase is e.g. the polyketide synthase from the cyanobacterium Synechococcus sp. strain PCC 7002 (SYNPCC7002 A1173), or an orthologue thereof, such as e.g. available from Cyanothece sp. PCC 7424, Cyanothece sp.
  • the cell of the invention expresses a codon-optimized nucleotide sequence coding for an olefm/polyketide synthase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 60.
  • the polyketide synthase is expressed in the cell of the invention in the form of several (e.g. two, three or four) individual polypeptide chains, each comprising one or more (preferably 2 or 3) individual modules of the synthase.
  • a first polypeptide may comprise the acyl-loading domain (LD) and the acyl-carrier protein domain (ACP-1)
  • a second polypeptide may comprise the ketosynthase (KS), acyltransferase (AT) and ketoreductase (K ) domains
  • a third polypeptide may comprise the acyl-carrier protein domain (ACP-2), the sulfotransferase (ST) domain and the thioesterase (TE) domain (as e.g.
  • each of the polypeptides comprising the synthase modules comprises a (different) affinity-tag and the cell expresses a scaffold protein that can accommodate each of the affinity-tags so as to bring together the synthase modules in the correct orientation.
  • the cell of the invention expresses three codon-optimized nucleotide sequence coding for three polypeptides which together comprise the modules of an olefm/polyketide synthase, the first polypeptide comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with amino acids 1 - 675 of SEQ ID NO: 61, the second polypeptide comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with amino acids 1 - 1254 of SEQ ID NO: 62, and the third polypeptide comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with amino acids 1 - 724 of SEQ ID NO: 63.
  • Suitable affinity tags that may be used include e.g. GBD (Kim A.S. et al, 2000, Nature. 404, (6774): 151- 158), SH3 (Nguyen, J.T. et al, 1998, Science 282 (5396): 2088-2092) and PDZ (Harris, B.Z. et al, 2001, Biochemistry 40 (20):5921-5930; Dueber, J.E. et al, 2003, Science 301 (5641): 1904-1908) ligands, which may be used in combination with a scaffold protein carrying the GBD (Kim A.S. et al, 2000, supra), the SH3 (Wu, X. et al, 1995, Structure. 3, (2):215-226) and PDZ (Schultz, J., et al, 1998, Nat Struct Biol. 5 (1): 19-24) binding domains, and preferably, having the amino acid sequence of SEQ ID NO: 64.
  • GBD
  • the invention relates to the biosynthesis of alkanes.
  • a two-step pathway is preferably used, which involves the reduction of acyl-CoA to fatty aldehydes by the action of fatty aldehyde- forming acyl- CoA reductases followed by the decarbonylation of the resulting aldehyde to alkane by aldehyde decarbonylases.
  • Suitable heterologous genes encoding fatty aldehyde- forming acyl-CoA reductases are available from e.g. Acinetobacter calcoaceticus (acrl) and Acinetobacter sp.
  • a cell of the invention preferably expresses a heterologous aldehyde decarbonylase such as e.g. the aldehyde decarbonylase from Synechococcus elongatus PCC7942 (PCC7942;_orfl593) and other orthologues recently reported by Schirmer (2010, Science, 329:559- 562).
  • a heterologous aldehyde decarbonylase such as e.g. the aldehyde decarbonylase from Synechococcus elongatus PCC7942 (PCC7942;_orfl593) and other orthologues recently reported by Schirmer (2010, Science, 329:559- 562).
  • the Arabidobsis CERl , CER3 CYTB5, or orthologues thereof are expressed in a cell of the invention for the synthesis of (very long chain) alkanes from (very long chain) acyl- CoAs in accordance with Bernard et al. (2012, supra).
  • alkane synthesis is the introduction of enzymes derived from insects in which aldehydes are converted to alkanes by a decarbonylation mechanism which results in the release of a CO group catalyzed by a NADPH- cytochrome P 45 o reductase (Qiu et al, 2012, Proc Natl Acad Sci USA,109: 14858-63).
  • the invention thus pertains to a modified eukaryotic microbial host cell.
  • the host cell preferably is modified to comprise: a) cytosolic expression of the enzymes of the fatty acid ⁇ -oxidation cycle in the absence of fatty acids and in the presence of a non-fatty acid carbon source; b) a metabolic route for producing under oxic conditions and preferably in the cytosol, acetyl-CoA from the non-fatty acid carbon source to feed into and drive the ⁇ -oxidation cycle in the bio synthetic direction; and, c) expression of a termination enzyme to convert reaction intermediates of the ⁇ - oxidation cycle into at least one fermentation product selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans-A 2 -fatty acid, an alkene, an alkane and derivatives thereof.
  • the acetyl-CoA is produced in the cytosol from pyruvate by at least one of: the following routes A, B, C and D.
  • the cell expresses a heterologous NAD + -dependent aldehyde dehydrogenase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 41
  • the cell expresses a heterologous ADP-forming acetyl-CoA synthetase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 40
  • the cell optionally, comprises a genetic modification that increases cytosolic pyruvate decarboxylase activity, and whereby the cell comprises a genetic modification that reduces or eliminates expression of endogenous ADHI gene or an orthologue thereof.
  • the cell expresses a heterologous acetylating NAD + -dependent acetaldehyde dehydrogenase comprising an amino acid sequence with at least 55% amino acid sequence identity to SEQ ID NO: 32, and whereby the cell comprises a genetic modification that reduces or eliminates expression of endogenous ADHI gene or an orthologue thereof and a genetic modification that reduces or eliminates expression of endogenous ALD6 gene or an orthologue thereof.
  • the cell expresses a heterologous pyruvate formate lyase comprising an amino acid sequence with at least 50% amino acid sequence identity to SEQ ID NO: 34, the cell expresses a heterologous pyruvate formate lyase activating enzyme comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 36, and whereby the cell comprises a genetic modification that reduces or eliminates expression of at least the endogenous PDC1 and PDC5 genes or orthologues thereof, and the cell, optionally, comprises a genetic modification that increases formate dehydrogenase activity.
  • the cell expresses a heterologous NAD + -dependent acetyl-transferring pyruvate dehydrogenase and whereby the cell comprises a genetic modification that reduces or eliminates expression of at least the endogenous PDC1 and PDC5 genes or orthologues thereof.
  • a modified cell according to the invention further preferably comprises one or more genetic modifications selected from the group consisting of: a) a genetic modification that reduces or eliminates fatty acid synthesis; b) a genetic modification that reduces or eliminates activity of the glyoxylate cycle; c) a genetic modification that reduces or eliminates activity of the tricarboxylic acid cycle; d) a genetic modification that reduces or eliminates transport of pyruvate into mitochondria; e) a genetic modification that reduces or eliminates transport of acetyl-CoA into mitochondria and f) a genetic modification that reduces or eliminates transport of glycerol.
  • a) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S.
  • the genetic modification is a modification that reduces or eliminates the expression of one or more of CIT2, ICL1, MLS1, MDH3, HAP2, HAP3, HAP4 and HAP5 genes or orthologues thereof; c) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae PDA1, PDB1, LAT1, LPD1, and PDX1 genes or orthologues thereof; d) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S.
  • the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae YAT1, YAT2 and CRC1 genes or orthologues thereof; and, f) the genetic modification is a modification that reduces or eliminates the expression of the S. cerevisiae FPS1 gene or an orthologues thereof.
  • the enzymes of the fatty acid ⁇ - oxidation cycle are expressed preferably in the cytosol, and preferably from promoters that are insensitive to catabolite repression.
  • the modified cell is a cell for producing fermentation products with a short chain-length, such as e.g. no more than C 8 , C 6 or C 4 .
  • the enzymes of the fatty acid ⁇ - oxidation cycle include: a) a thiolase with a short chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 43, 44 and 80; b) an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity, whereby, preferably, the 3- hydroxybutyryl-CoA dehydrogenase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 47 and 48; c) a crotonase, whereby, preferably, the crotonase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 50 and 51; and, d) a NADH-dependent trans-2-enoyl-CoA reductase, whereby, preferably, the trans-2-enoy
  • the modified cell is a cell for producing fermentation products with a longer chain-length, such as e.g. at least C 6 , C 8 , or C 10 .
  • the enzymes of the fatty acid ⁇ -oxidation cycle include: a) at least one of a peroxisomal thiolase that lacks a functional peroxisomal targeting signal and a heterologous thiolase with a broad chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 42 and 45; b) at least one of a peroxisomal enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities that lacks a functional peroxisomal targeting signal and a heterologous enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities with a broad chain-
  • a modified cell according to the invention can further comprise a) expression of an enzyme with acetyl-CoA carboxylase activity, whereby preferably the acetyl-CoA carboxylase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 9 and 54; and, b) expression of an enzyme with acetoacetyl-CoA synthase activity, which catalyses the decarboxylative condensation of acetyl-CoA and malonyl-CoA to form acetoacetyl-CoA, whereby preferably the acetoacetyl-CoA synthase comprises an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 55.
  • the cell can comprise this alternative route for producing acetoacetyl-CoA, in addition to but preferably as an alternative for the thiolase with short chain-length specificity in the event that products are produced not having a longer chain-length than C 4 .
  • the alternative route for producing acetoacetyl-CoA is expressed in addition to the peroxisomal thiolase or the heterologous thiolase with a broad chain-length specificity, which are then needed for further rounds of the reverse ⁇ -oxidation cycle.
  • a preferred modified cell of the invention is a cell for producing butanol, wherein the cell expresses termination enzymes that catalyze the conversion of butyryl- CoA via butaldehyde to butanol, whereby, preferably the enzymes are selected from: a) a NADH-dependent enzyme having both aldehyde and alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 57; and, b) a NADH-dependent aldehyde dehydrogenase, preferably comprising an amino acid sequence with at least 55% amino acid sequence identity with SEQ ID NO: 32, expressed together with a NADH-dependent alcohol dehydrogenase preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 56.
  • a further preferred modified cell of the invention is a cell for producing 1,3- butanediol, wherein cell expresses termination enzymes that comprise an acetoacetyl- CoA reductase and at least one of a butyraldehyde dehydrogenase and an alcohol/aldehyde dehydrogenase, whereby, preferably, the enzymes are selected from: a) an acetoacetyl-CoA reductase comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 81; and at least one of: b) a butyraldehyde dehydrogenase comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 82; and, c) a NADH-dependent enzyme having both aldehyde and alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 57.
  • Another preferred modified cell of the invention is a cell for producing an alcohol with a chain-length greater than C 6 and preferably including dodecanol, wherein the cell expresses termination enzymes having fatty acyl-CoA reductase activity, whereby, preferably the enzymes are selected from: a) a NADH-dependent alcohol forming fatty acyl-CoA reductase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 58; and, b) an NADH-dependent alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 59.
  • Still another preferred modified cell of the invention is a cell for producing an alkene, wherein the cell expresses a termination enzyme having olefin synthase activity, whereby preferably, the enzyme is selected from: a) a polyketide synthase comprising an amino acid sequence with at least 50% amino acid sequence identity with SEQ ID NO: 60; and, b) a polyketide synthase as defined in b) wherein the synthase is expressed in the form of more than one individual polypeptide chains, each comprising individual modules of the synthase.
  • a termination enzyme having olefin synthase activity whereby preferably, the enzyme is selected from: a) a polyketide synthase comprising an amino acid sequence with at least 50% amino acid sequence identity with SEQ ID NO: 60; and, b) a polyketide synthase as defined in b) wherein the synthase is expressed in the form of more than one individual polypeptide chains, each comprising individual modules of the syntha
  • Another preferred modified cell of the invention is a cell for producing a fatty acid, preferably including dodecanoic acid, wherein the cell expresses a termination enzyme that catalyze the deacylation of acyl-CoA thioesters to fatty acids and CoA, whereby, preferably, the enzyme is an acyl-CoA thioesterase comprising an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO: 74 and SEQ ID NO: 75.
  • the modified eukaryotic microbial host cell according to the invention preferably is a fungal cell, more preferably a yeast cell, and most preferably the cell is a cell of a yeast genus selected from the group consisting of Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Cryptococcus, Debaromyces, Saccharomycecopsis, Saccharomycodes, Wickerhamia, Debayomyces, Hanseniaspora, Ogataea, Kuraishia, Komagataella, Metschnikowia, Williopsis, Nakazawaea, Torulaspora, Bullera, Rhodotorula, and Sporobolomyces.
  • Saccharomyces Kluyveromyces
  • Candida Pichia
  • Schizosaccharomyces Hansenula
  • Kloeckera
  • the cell is a cell of a yeast species selected from the group consisting of Saccharomyces cerevisiae, S. exiguus, S. bay anus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei, S. lactis, S. marxianus, S. microellipsoides, S. montanus, S. norbensis, S. oleaceus, S. paradoxus, S. pastorianus, S. pretoriensis, S. rosei, S. rouxii, S. uvarum, S.
  • yeast species selected from the group consisting of Saccharomyces cerevisiae, S. exiguus, S. bay anus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei
  • a preferred modified cell of the invention has the ability to grow on a hexose, preferably glucose, at a rate of at least 0.01, 0.02, 0.05, 0.1, 0.2, 0.25 or 0.3 h "1 under aerobic conditions. 7. Processes wherein the host cells of the invention are used for the production various compounds
  • the invention relates to the use of a cell according to the invention for the preparation of at least one fermentation product that is or is derived from an intermediate in the ⁇ -oxidation cycle with a carbon chain-length of at least C 4 , whereby, preferably, the fermentation product is selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans-A 2 -fatty acid, a trans- ⁇ 2 - fatty acid, an alkene, an alkane and derivatives thereof.
  • the cell according to the invention is preferably used to produce the fermentation product in a process as defined herein below.
  • the invention relates to processes for the production of these compounds by the host cells of the invention.
  • the invention relates to a process for producing at least one fermentation product that is or is derived from an intermediate in the ⁇ -oxidation cycle with a carbon chain-length of at least C 4 , or wherein, more preferably, the fermentation product is selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans- ⁇ 2 - fatty acid, a trans- ⁇ 2 - fatty acid, an alkene and derivatives thereof.
  • the process preferably, comprises the step of: a) fermenting a medium with a cell according to the invention, preferably under oxic conditions, whereby the medium contains or is fed with a non-fatty acid carbon source and whereby the yeast cell ferments the non-fatty acid carbon source to the fermentation product.
  • the yeast cell preferably is a (host) cell as herein defined above.
  • the process preferably comprises a further step wherein the fermentation product is recovered.
  • the process may be a batch process, a fed-batch process or a continuous process as are well known in the art.
  • the non-fatty acid carbon source preferably at least comprises a source of hexoses or multimers of hexoses that are assimilable by the cell, e.g. a yeast cell.
  • a source of hexoses or multimers of hexoses that are assimilable by the cell, e.g. a yeast cell.
  • assimilable hexoses or multimers thereof include e.g. glucose, fructose, galactose, mannose, maltose, saccharose, lactose and maltodextrines.
  • the source of hexose comprises or consists of at least glucose.
  • the medium fermented by the cells of the invention comprises or is fed with (fractions of) hydrolyzed biomass comprising at least one at least a hexose such as glucose.
  • biomass is understood to mean the biodegradable fraction of products, waste and residues from biological origin from agriculture (including vegetal, such as crop residues, and animal substances), forestry (such as wood resources) and related industries including fisheries and aquaculture, as well as biodegradable fraction of industrial and municipal waste, such as municipal solid waste or wastepaper.
  • the biomass is plant biomass, more preferably a fermentable hexose/glucose/sugar-rich biomass, such as e.g. sugarcane, a starch-containing biomass, for example, wheat grain, or corn straw.
  • plant biomass is cereal grains, such as corn, wheat, barley or mixtures thereof.
  • hydrolyzed biomass to be fermented in the processes of the invention is e.g. hydrolyzed cereal biomass.
  • Methods for hydrolysis of biomass such as cereal are known in the art per se and include e.g. vapor and enzymes such as glucoamylases.
  • Another example of hydrolyzed biomass to be fermented in the processes of the invention is e.g. hydrolyzed sugarcane biomass.
  • Methods for hydrolysis of biomass such as sugarcane are also known in the art per se and include e.g. vapor.
  • the sources of glucose may be glucose as such (i.e. as monomeric sugars) or it may be in the form of any carbohydrate oligo- or polymer comprising glucose units, such as e.g. sugar cane, starch and the like.
  • appropriate carbohydrases such as glucanases, amylases, and the like
  • the modified host cell may be genetically engineered to produce and excrete such carbohydrases.
  • the fermentation medium will further comprise the appropriate ingredients required for growth of the modified host cell.
  • Compositions of fermentation media for growth of eukaryotic microorganisms such as yeasts are well known in the art.
  • the fermentation process may be an oxic (aerobic) or an anoxic (anaerobic) fermentation process.
  • the process of the invention is an oxic (aerobic) fermentation process as herein defined above.
  • the rate of oxygen consumption is at least 5.5, more preferably at least 6 and even more preferably at least 7 mmol/L/h.
  • the yeast cell of the invention consumes less than 30, 20, 18, 15, 12, 10, 8 or 5% of the amount of oxygen on a C-molar basis related to the carbon source consumed during the conversion of the carbon source into the fermentation product.
  • the conversion coefficient of oxygen consumed over substrate utilized on a C-molar basis (C os ) is herein understood to mean mol 0 2 used per C-mol carbon source consumed.
  • C os The conversion coefficient of oxygen consumed over substrate utilized on a C-molar basis
  • the fermentation process is preferably run at a temperature that is optimal for the modified cells of the invention.
  • the fermentation process is performed at a temperature which is less than 42°C, preferably less than 38°C.
  • the fermentation process is preferably performed at a temperature which is lower than 35, 33, 30 or 28°C and at a temperature which is higher than 20, 22, or 25°C.
  • the volumetric productivity of the fermentation product preferably is at least 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0 or 10.0 g fermentation product per liter per hour.
  • the yield of the fermentation product on glucose in the process preferably is at least 50, 60, 70, 80, 90, 95 or 98%.
  • the yield is herein defined as a percentage of the theoretical maximum yield on glucose, which is for the following products in gram product per gram glucose:
  • 1-butanol 0.41, 1,3-butanediol: 0.50, dodecanol: 0.34, dodecanoic acid: 0.37 and tridecene: 0.29, palmitic acid: 0.36 and heptadecene: 0.30.
  • FIG 1. A general pathway overview of a engineered yeast cell (e.g. S. cerevisiae) according to the invention wherein glucose is metabolized via pyruvate to acetyl-CoA to feed into a reversed ⁇ -oxidation cycle that is expressed in the cytosol of the yeast cell.
  • Figure 2. Physical map of plasmid pUG6 (Guldener et al, 1996, Nucleic Acids Res., 24:2519-2524)
  • Figure 3 Physical map of plasmid pSH47 (Guldener et al, 1996, Nucleic Acids Res., 24:2519-2524)
  • Figure 4 Schematic depiction of expression cassette for expression of aldp A and ACS SE used for genomic integration into the S. cerevisiae FPS1 locus.
  • Figure 5 Schematic depiction of expression cassette for expression of E. coli mhpF, used for genomic integration into the S. cerevisiae ALD6 locus
  • Figure 6 Schematic depiction of expression cassette for expression of aldp A and ACS SE used for genomic integration into the S. cerevisiae HO locus.
  • Figure 7 Physical map of plasmid pMA-C12-l as constructed in Example 6.
  • Figure 8 Physical map of plasmid pMA-C4-l as constructed in Example 7.
  • Figure 9 Physical map of plasmid pMA-Tl-C12 as constructed in Example 8.
  • Figure 10 Physical map of plasmid pMA-T7-C4 as constructed in Example 8.
  • Figure 11 Physical map of plasmid pRSJCl as constructed in Example 9.
  • Figure 12 Physical map of plasmid pRSJCl as constructed in Example 9.
  • Figure 13 Fermentation of strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3) transformed with plasmids pMA-C4-l and pMA-T6-C4 in a 5L Labfors fermenter. Concentrations of cell dry weight (g/L), butanol ⁇ g/L), ethanol (mg/L), acetic acid (mg/L) and glycerol (mg/L) are indicated over time.
  • Cell extracts for activity assays are prepared from exponentially growing aerobic or anaerobic batch cultures and analyzed for protein content as described by Abbot et al, (2009, Appl. Environ. Microbiol. 75 : 2320-2325).
  • NAD + -dependent acetaldehyde dehydrogenase (EC 1.2.1.10) activity is measured at 30°C by monitoring the oxidation of NADH at 340 nm.
  • the reaction mixture (total volume 1 ml) contains 50 mM potassium phosphate buffer (pH 7.5), 0.15 mM NADH and cell extract.
  • the reaction is started by addition of 0.5 mM acetyl-Coenzyme A.
  • the activity of pyruvate formate-lyase is estimated spectrophotometrically by recording the change in absorption at 340 nm at 35°C.
  • the assay mixture of pyruvate formate-lyase contains 20 mM sodium pyruvate, 0.08 mM coenzyme A, 1 mM NAD, 6 mM sodium DL-malate, 2 mM dithiothreitol, 1.1 U of citrate synthase (pig heart, EC 4.1.3.7) per ml, 22 U of malate dehydrogenase (pig heart, EC 1.1.1.37) per ml, and cell- free extract in 100 mM potassium phosphate buffer (pH 7.6) (Takahashi et al, 1982, J. Bacteriol. 149: 1034-1040).
  • Thiolase activity is measured by monitoring the disappearance of acetoacetyl- CoA, corresponding to the thiolysis direction of the enzymatic reaction.
  • the disappearance of acetoacetyl-CoA is monitored by the decrease in absorbance at 303 nm, which is the characteristic absorption band of an enolatecomplex formed by acetoacetyl-CoA with Mg 2+ .
  • the reaction mixture contains 100 mM Tris-HCl, pH 8.0, 10 mM MgS04, 200 ⁇ acetoacetyl-CoA, 200 ⁇ CoA, and cell extract prepared as described above.
  • a standard curve is constructed by measuring the absorbance of acetoacetyl-CoA at different concentrations with 10 mM Mg 2+ (Shen et al, 201 1, Appl Environ Microbiol, 77:2905-15).
  • the hydroxyacyl-CoA dehydrogenase activity is measured by monitoring the decrease of absorption at 340 nm, corresponding to consumption of NADH.
  • the reaction mixture contains 100 mM 3-(N-morpholino) propanesulfonic acid (MOPS), pH 7.0, 200 _M NADH, 200 ⁇ acetoacetyl-CoA, and crude cell extract. The reaction is initiated by the addition of the cell extract. (Shen et al., 2011, supra).
  • the enoyl-CoA hydratase activity is measured by the decrease of absorption at 263 nm, corresponding to disruption of the ⁇ - ⁇ unsaturation of crotonyl-CoA.
  • the assay mixture contains 100 mM Tris-HCl pH 7.6, 100 ⁇ crotonyl-CoA, and the crude extract. The reaction is initiated by the addition of the cell extract.
  • the standard curves for crotonyl-CoA and 3-hydroxybutyryl-CoA are constructed by measuring the absorbance of the two compounds at 263 nm at different concentrations. (Shen et al, 2011, supra).
  • the trans enoyl-CoA reductase activity for crotonyl-CoA is measured at 340 nm.
  • the reaction mixture contains 100 mM potassium phosphate buffer, pH 6.2, 200 ⁇ NADH, 200 ⁇ crotonyl-CoA, and crude extract.
  • the reaction is initiated by the addition of the extract.
  • the reaction mixture contains 1 mM NAD + , 0.4 mM butyryl-CoA, and crude extract in 100 mM Tris HC1, pH 7.5.
  • the absorbance is monitored at 340 nm at 30°C.
  • the reaction is initiated by the addition of the extract.
  • the aldehyde and alcohol dehydrogenase activities of AdhE2 are measured by monitoring the decrease of absorbance at 340 nm corresponding to the consumption of NADH or NADPH.
  • the reaction mixture contains 100 mM Tris-HCl, pH 7.5, 5 mM dithiothreitol (DTT), 300 ⁇ NADH, and 1 mM butyryl-CoA for the butyraldehyde dehydrogenase (BYDH) reaction and 50 mM butyraldehyde for the butanol dehydrogenase (BDH) reaction.
  • the reaction is initiated by the addition of the extract. (Shen et al, 2011, supra).
  • NADH assay A fluorescent NAD/NADH detection kit purchased from Cell
  • Cells are harvested by centrifugation at 13,200 rpm at 4°C. The pellets are then resuspended with 0.2 ml of the NAD/NADH extraction buffer and 0.2 ml of the lysis buffer (provided). Lysis is allowed to proceed for 10 to 20 min at 60°C until the cell resuspension turns clear. The lysate is then centrifuged at 8,000 rpm for 5 min at 4°C. The supernatant is retrieved for subsequent NADH assays. For the measurement of intracellular NADH levels, the cell lysates are mixed with the enzyme and the fluorescent detection reagent provided in the kit. The reaction is allowed to proceed for 1 to 1.5 h at room temperature in the dark, and then readings are taken with excitation at 530 to 570 nm and emission at 590 to 600 nm.
  • strain construction The construction of the strains featured in the following examples is based on strain CEN.PK2-1C (MATa; ura3-52; trpl-289; leu2-3,1 12; his3A 1 ; MAL2-8 C ; SUC2). For further details on this strain see:
  • Table 4 Overview of plasmids used for the strain construction (the plasmids are featured in the following Examples)
  • Ec Escherichia coli
  • Td Treponema denticola
  • Sc Saccharomyces cerevisiae
  • Clostridium acetobutylicum Eg, Euglena gracilis; Hs, Homo sapiens; Cb, Clostridium beijerinckii, 1 ,3-BDO, 1,3-butanediol.
  • Table 5 Overview of basis strains for the strain construction (the construction of the strains is described in Examples 1 to 5).
  • a deletion cassette is amplified from plasmid pUG6 (Guldener et al, 1996, Nucleic Acids Research, 24:2519-2524; Figure 2) via PCR with the following oligonucleotides:
  • AGC ATA GGC CAC TAG TGG ATC TG-3' (SEQ ID NO: 66)
  • a deletion cassette is amplified from plasmid pUG6 (Guldener et al, 1996, supra; Figure 2) via PCR with the following oligonucleotides:
  • the sequential deletion of gene adhl and fpsl in one strain is accomplished by recovering the kanMX marker in the strain resulting from example 1 (adhl deletion strain) via the cre-recombinase procedure described by Guldener et al., (1996, supra) and transforming the resulting yeast strain with the fpsl deletion cassette (see above).
  • the cre-recombinase procedure requires the transformation of the yeast strain with the plasmid pSH47 (see Figure 3), which carries the gene for the cre-recombinase. This enzyme is able to recombine the two loxP sites flanking the kanMX resistance gene.
  • This recombination event leads to a loss of this marker gene leaving one loxP site at the target locus (in the present example locus adhl).
  • the yeast strain is cultivated for at least 10 generations in WMVIII (Lang and Looman, 1995 Appl Microbiol Biotechnol, 44(1-2): 147-56) containing uracil. Colonies, which have lost the plasmid pSH47 are identified via counter selection on plates with 5- fluoroorotic acid and picked for further construction purposes.
  • Example 3 Deletion of the gene FPS1 and expression of the P. aeruginosa aldpA and S. enterica acssrjgenes
  • the P. aeruginosa aldp A gene (codon optimized for yeast: SEQ ID NO: 84) and the S. enterica acss E gene are synthesized (codon optimized for yeast: SEQ ID NO: 85) at GenScript USA Inc. (www.genscript.com) in one cluster (gene cassette).
  • Example 4 Deletion of the gene ALD6 and expression of the E. coli mhpF gene
  • the E. coli mhpF gene is synthesized (codon optimized for yeast: SEQ ID NO:
  • ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http://www.yeastgenome.org/cgi-
  • Example 5 Expression of the genes P. aeruginosa aldpA and S. enterica acssgjn the HO locus
  • the P. aeruginosa aldp A gene (codon optimized for yeast: SEQ ID NO: 84) and the S. enterica acss E gene are synthesized (codon optimized for yeast: SEQ ID NO: 85) at GenScript USA Inc. (www.genscript.com) in one cluster (gene cassette).
  • the URA3 marker gene for selection in yeast the URA3 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/c
  • Example 6 Expression of genes for the production of long chain compounds (e.g. C12) (with plasmid pMA-C12-l and pMA-C12-2
  • the Ci2 gene cassette 1 is synthesized by GenScript USA Inc. (www.genscript.com) and cloned into plasmid pMA via the Kpnl restriction site resulting in plasmid pMA-C12-l; see Figure 7).
  • the pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA see: SEQ ID NO: 70).
  • a CEN/ARS sequence SEQ ID NO: 71
  • the LEU2 expression cassette for selection of positive transformants (the LEU2 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi- bm/getSeq?
  • strains resulting from Examples 3, 4 and 5 are used for transformation with plasmid pMA-C 12-1.
  • the corresponding yeast strains are transformed with pMA-C12-l via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking leucine for the selection of leucine prototrophic strains (transformants carrying the plasmid pMA-C12-l).
  • Example 6 Another variant of Example 6 is the construction and transformation of plasmid pMA-C12-2 in the corresponding yeast strains.
  • This plasmid is analogous to plasmid pMA-C12-l except that POT1 (S. cerevisiae), FOX2 (S. cerevisiae) genes (both without PTS) are used instead of FadA (E. coli) and FadB (E. coli).
  • POT1 S. cerevisiae
  • FOX2 S. cerevisiae
  • FadB E. coli
  • the gene Ter T. denticola
  • Example 7 Expression of genes for the production of short chain compounds (e.g. C4) (with plasmids pMA-C4-l and pMA-C4-2
  • the C4 gene cassette 1 is synthesized by GenScript USA Inc. (www. enscript.com) and cloned into plasmid pMA via the restriction site Kpnl resulting in plasmid pMA-C4-l; see Figure 8).
  • the pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA please see SEQ ID NO: 70).
  • the cassette contains in one cluster a CEN/ARS sequence (SEQ ID NO: 71) for autonomous replication and segregation in yeast, the LEU2 expression cassette for selection of positive transformants (the LEU2 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi- and codon optimized variants (codon optimized for S. cerevisiae) of the genes ERG 10 (S. cerevisiae), Hbd (C. acetobutylicum), crt (C. acetobutylicum) and Ter (T. denticola).
  • a CEN/ARS sequence SEQ ID NO: 71
  • the LEU2 expression cassette for selection of positive transformants (the LEU2 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi- and codon optimized variants (codon optimized for S. cerevisiae) of the genes ERG 10 (S
  • strains resulting from Examples 3, 4 and 5 are used for transformation with plasmid pMA-C4-l .
  • the corresponding yeast strains are transformed with pMA-C4-l via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking leucine for the selection of leucine prototrophic strains (transformants carrying the plasmid pMA-C4-l).
  • Example 7 Another variant of Example 7 concerns the construction and transformation of plasmid pMA-C4-2 in the corresponding yeast strains.
  • This plasmid is analogous to plasmid pMA-C4-l except that atoB (E. coli), Hbd (C. beijerinckii), crt (C. beijerinckii)) and Ter (E. gracilis) genes are used instead of ERG10 (S. cerevisiae), Hbd (C. acetobutylicum), crt (C. acetobutylicum) and Ter ( T. denticola), respectively.
  • atoB E. coli
  • Hbd C. beijerinckii
  • crt C. beijerinckii
  • Ter E. gracilis
  • Example 7 concerns the construction and transformation of plasmid pMA-C4-3 in the corresponding yeast strains.
  • This plasmid is analogous to plasmid pMA-C4-l except that the plasmid only contains the genes ERG 10 (S. cerevisiae) and Hbd (C. acetobutylicum) and the corresponding promotors and terminators.
  • Example 8 Expression of termination enzymes
  • Plasmids pMA-Tl-C12, pMA-T2-C12, pMA-T4-C12, pMA-T5-C12 are used in combination with plasmids pMA-C12-l and pMA-C12-l (see Example 6) for the production of long chain compounds (in particular C12) and plasmids pMA-T6-C4 and pMA-T7-C4 were used in combination with plasmids pMA-C4-l and pMA-C4-l (see Example 7) for production of short chain compounds (in particular C 4 ).
  • E. coli fadM or H. sapiens hBACH or M. musculus PTE-2 or E. gracilis FAR or E. coli yiaY or C. acetobutylicum adhE2 or E. coli mhpF+FucO are synthesized by GenScript USA Inc. (www .
  • the pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA see SEQ ID NO: 70).
  • the cassettes contain in one cluster a CEN/ARS sequence (SEQ ID NO: 71) for autonomous replication and segregation in yeast, the HIS3 expression cassette for selection of positive transformants after transformation (the HIS3 coding region including 500 bp upstream and 200 bp downstream, for sequence see: http : ⁇ www.yeastgenome.org/cgi- and codon optimized variants (codon optimized for S. cerevisiae) of the genes E. coli fadM or H. sapiens hBACH or E. gracilis FAR or E. coli yiaY or C. acetobutylicum adhE2 or E. coli mhpF+FucO.
  • a CEN/ARS sequence SEQ ID NO: 71
  • the HIS3 expression cassette for selection of positive transformants after transformation
  • the HIS3 coding region including 500 bp upstream and 200 bp downstream, for sequence see: http : ⁇ www.yeastgenome.org/cgi-
  • strains resulting from Examples 6 and 7 are used for transformation with plasmids pMA-Tl-C12, pMA-T2-C12, pMA-T4-C12, pMA-T5-C12, pMA-T6-C4 and pMA-T7-C4.
  • the strains were transformed via the lithium acetate method described by Gietz et al. (1992, supra) and were cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking histidine for the selection of histidine prototrophic strains (transformants carrying plasmids pMA-Tl-C12 or pMA-T2-C12 or pMA-T4-C12 or pMA-T5-C12 or pMA-T6-C4 or pMA-T7-C4).
  • Two centromeric expression vectors pRSJCl and pRSJC2 are constructed for expression in S. cerevisiae CEN.PK strains of an OLS gene from Synechococcus sp strain PCC7002, which encodes an alfa-olefme synthase (SYNPCC7002 A1173).
  • the OLS open reading frame encodes a multimodular Ols protein with eight distinguishable structural modules in a single polypeptide chain and each module has a different enzymatic activity (Mendez-Perez et al, 2012, supra).
  • the pRSJCl vector is constructed to express the full-length Ols protein and the pRSJC2 vector is constructed for expression of three independent polypeptide chains (mOLs 1, 2 and 3) that together comprises all the different modules of the Ols protein. The latter will be expressed in combination with a molecular scaffold.
  • the complete, full length OLS gene is cloned into a centromeric pRSJCl vector ( Figure 11) that is constructed by ligating a 4.442 bp fragment from the shuttle pRS316 vector (Sikorski and Hieter, 1989, Genetics, 122: 19) generated by PvuW digestion -to delete a 445bp fragment containing its multiple cloning site (MCS, 103bp)- to a 1357 bp PvuW fragment of the pESC vector (Stratagene), which contains the S. cerevisiae GAL1 and GAL 10 promoters in opposite orientation, two MCS sequences MCS1 and MCS2, and a transcription termination sequence downstream of each promoter.
  • the OLS sequence will be cloned between the Spel and Sad sites of MCS1 in pRSJCl to produce a plasmid designated as pOLS-JAMl .
  • OLS1, OLS2 and OLS3 Three DNA sequences named OLS1, OLS2 and OLS3, encoding three independent Ols-protein submodules - mOlsl, m01s2 and m01s3 (with amino acid sequences as depicted in SEQ ID NO's: 61, 62 and 63, respectively) - are synthesized, cloned and expressed from the two pRSJC vectors, pRSJCl and -2 ( Figure 1 1 and 12), that are constructed in this work.
  • the OLS1 sequence is cloned in the MCS2 of the above described pRSJCl vector (URA3 marker) under the control of the GALl promoter; in addition, a DNA sequence encoding a synthetic protein scaffold (SCA; having the amino acid sequence depicted in SEQ ID NO: 64) is synthesized and cloned in the MCS1 of pRSJCl under the control of the GAL10 promoter to produce plasmid pOLSl/SCA-JAM2.
  • the synthetic SCA sequence encodes three modular protein-protein interaction domains: the GTPase binding domain (GBD) from the rat actin polymerization switch N-WASP (Kim A.S.
  • pRSJC2 The OLS2 and OLS3 sequences are both cloned in pRSJC2: OLS2 at the MCS1 under the control of the GAL10 promoter and OLS3 at MCS2 under the control of the GALl promoter, to produce pOLS2/pOLS3-JAM3.
  • pRSJC2 Figure 12 is almost identical in features to pRSJCl, differing only in the auxotrophic marker (TRPI).
  • pRSJC2 For construction of pRSJC2, the above indicated 1357 bp Pvull fragment from the pESC vector containing the GAL1-GAL10 yeast promoter is subcloned into a 4338 bp derivative of pRS314 (TRPI; (Sikorski and Hieter, 1989, supra) obtained by deletion of the MCS with Pvull.
  • GBD ligand (interaction partner WASP GBP, amino acid sequence:
  • LVGALMHVMQRSRAIHSSDEGEDQAGDEDED; SEQ ID NO: 76; Kim A.S. et al., 2000, supra) is fused onto the C terminus of Olsl .
  • the SH3 ligand (interaction partner Crk SH3, amino acid sequence: PPPALPPKRRR; SEQ ID NO: 77; Nguyen, J.T. et al., 1998, supra) is fused onto the C terminus of 01s2.
  • the PDZ ligand Syn PDZ interaction partner, amino acid sequence: GVKESLV; SEQ ID NO: 78; Harris, B.Z. et ah, 2001, Dueber, J.E. et ah, 2003) is fused onto the C-terminus of 01s3.
  • the strains resulting from Example 6 are used for transformation with plasmid pOLS-JAMl, or with plasmids pOLSl/SCA-JAM2 and pOLS2/pOLS3-JAM3.
  • the marker is recycled before transformation with plasmids pOLS-JAMl, or with plasmids pOLSl/SCA-JAM2 and pOLS2/pOLS3-JAM3. Therefore the strains are cultivated in WMVIII medium supplemented with 100 mg/L of uracil for 48 h to ensure growth of cells, which have lost the URA3 marker by pop-out via homologous recombination. Afterwards the cells are plated on YE -medium agar plates supplemented with 1.5 g/L 5'-FOA (5- fluoroorotic acid) for the selection of uracil auxotrophic cells.
  • the strains were transformed via the lithium acetate method described by Gietz et al. (1992, supra) and were cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking uracil for the selection of uracil prototrophic strains (pOLS-JAMl transformants) or agar plates lacking uracil and tryptophan for the selection of uracil/ tryptophan prototrophic strains (transformants of pOLSl/SCA-JAM2 and pOLS2/pOLS3-JAM3).
  • Example 10 Cultivation procedure for strain evaluation (growth and productivity) The standard cultivation procedure for the strains of the yeast Saccharomyces cerevisiae was:
  • Strains with the genetic background of CEN.PK2-1C are auxotrophic for leucine, histidine, uracil and tryptophan. Therefore the medium was supplemented with leucine (400 mg/L), histidine (100 mg/L), uracil (100 mg/L) and tryptophan (100 mg/L) where necessary (to establish selection pressure on plasmids, plasmid containing strains were cultivated in medium lacking the corresponding supplement).
  • Composition of WMVIII medium (for 1L); according to Lang and Looman, 1995: 50 g sucrose, 250 mg NH 4 H 2 P0 4 , 2,8 g NH 4 C1, 250 mg MgCl 2 x 6H 2 0, 100 mg CaCl 2 x 2H 2 0, 2 g KH 2 P0 4 , 550 mg MgS0 4 x 7H 2 0, 75 mg meso-Inositol and 10 g Na-glutamate.
  • Trace elements lOOOx concentrated: 1,75 g ZnS0 4 x 7H 2 0; 0,5 g Fe 2 S0 4 x 7 H 2 0; 0,1 g CuS0 4 x 5 H 2 0; 0,1 g MnCl 2 x 4 H 2 0; 0,1 g NaMo0 4 x 2 H 2 0, (for one liter).
  • Vitamin solution 25 Ox concentrated: 2,5 g Nicotinic acid; 6,25 g Pyridoxine; 2,5 g Thiamine; 0,625 g Biotine; 12,5 g Ca-Pantothenate, (for one liter).
  • Example 11 Metabolite analysis (identification and quantification of n-alcohols and fatty acids)
  • n-alcohols were conducted through gas chromatography- mass spectroscopy (GC-MS) following a modification of the method reported by Atsumi (2008).
  • the analysis was performed on an AGILENT(TM) 6890 GC/5973 MS (AGILENT TECHNOLOGIES,(TM) Palo Alto, CA) instrument with a HP-5ms capillary column (30 m x 0.25 mm x 0.25 ⁇ ).
  • AGILENT TECHNOLOGIES,(TM) Palo Alto, CA HP-5ms capillary column (30 m x 0.25 mm x 0.25 ⁇ ).
  • 2 ml of culture broth (supernatant and cells) were mixed with 0.8 g of glass beads for cell disruption.
  • HPLC high-performance liquid chromatography
  • the temperature was then raised with a gradient of 15° C/min to 230° C and held for 4 min.
  • Helium (1 ml min-1, MATHESON TRI-GAS,(TM) Longmont, CO) was used as the carrier gas.
  • the injector and detector were maintained at 250° C. A 0.5- ⁇ 1 sample was injected in splitless injection mode.
  • the resulting fatty acids methyl esters were quantified according to the following method: 50° C held for 1 min, 30° C/min to 160° C, 15° C/min to 200° C, 200° C held for 1.5 min, 10° C/min to 225° C, and 225° C held for 15 min.
  • Quantification of glycerol Cell free supernatants of sampled cell suspensions of 1 ml are analyzed for extracellular glycerol by centrifugation at 3500 x g for 5 min and subsequent enzymatic determination of the glycerol content of the supernatant using commercial glycerol analysis kits (Free Glycerol Determination Kit, Sigma- Aldrich).
  • cell dry weight is determined by harvesting 3 x 6 ml of culture after the desired cultivation time. The culture is centrifuged at 3500 x g for 5 min. Afterwards, the cells are washed once with H 2 0 and the pellet is weighted by a scale after vacuum-drying for 12 h at 80 °C in a cabinet desiccator and cooling to room temperature in a dehydrator.
  • Lipid and hydrocarbon extraction Cells were harvested by centrifugation, resuspended in 3 mL of H 2 0 containing 50mg of hexadecane as an internal standard. (Mendez-Perez et al, 2011, Appl Environ Microbiol. 77(12):4264-7) Lipid and hydrocarbons were purified and analyzed by GC-MS as described in Lennen et al. (2010 Biotechnol Bioeng. 106(2): 193-202).:
  • lipids are extracted in a five-step procedure as described by Tronchoni et al. (2012, Int J Food Microbiol. 155(3): 191-8).
  • DMDS derivation All chemicals were purchased from Sigma-Aldrich unless otherwise noted. To the dried hydrocarbon extract, ⁇ of dimethyl disulfide (Acros Organics) and 100 of carbon disulfide containing 6 mg/mL of iodine were added (according to Vicenti et al. 1987, Anal Chem. 59:694). The reaction mixture was kept at 60°C and after 40 hr, the reaction was quenched with aqueous Na 2 S 2 0 3 (3xlO "4 M, Acros Organics) and the organic phase was then evaporated to dryness under a nitrogen stream and dissolved in hexane to be analyzed by GC-MS (Mendez-Perez et al. 2011, supra). Alternatively, the procedure described by Rude et al. (2011, Appl. Environ. Microbiol. 7: 1718-1727) is used.
  • Permanganate/periodate oxidation Isolation of the hydrocarbon for permanganate/periodate oxidation was performed by flash chromatography using a Pasteur pipette packed with silica gel (Silia flash P60, 40-63 ⁇ . 60A, Silicycle). The sample was applied after solvating the silica gel column with 8-10 column volumes of hexane. Five fractions were collected and analyzed by thin layer chromatography using commercial glass plates coated with silica gel. Spots were visualized using a permanganate solution. After identifying fractions containing the desired compound (verified by GC-MS), permanganate/periodate oxidation was used to identify the position of the double bond.
  • Permanganate/periodate oxidation was done as described before (according to Goodloe et al. 1982, Biochimica et Biophysica Acta 710: 485- 492): the sample was dried under nitrogen and 0.3 ml of t-butanol, 0.1 ml of Na 2 CC"3 (0.02M) and 0.12 ml of NaI0 4 /KMn0 4 (2.1mg/ml and 1.6 ml/ml respectively) were added to the dried extract. Reaction was maintained at 28°C with shaking for 6 hr.
  • Branched point locations of hydrocarbons were determines by the presence of characteristic secondary CnH2n-l fragment ions as described by Koster et al. (1999, Organic Geochemistry, 30 (11): 1367-1379).
  • Table 6 presents the results of shake flask fermentations as obtained with the various background strains as indicated, and transformed with plasmids as indicated.
  • Table 6 presents for each of the transformed strains the yields of biomass (cell dry weight) and product of interest (as indicated), as well as the yields of the by-products ethanol and glycerol, after 24 hours of cultivation.
  • the strains were cultivated under the conditions described in Example 10.
  • Example 13 Fermentation in Labfors fermenter
  • Strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3) transformed with plasmids pMA-C4-l and pMA-T6-C4 was cultured in a 5L Labfors fermenter. The strain was precultured in 20 ml of WMVIII medium supplemented with 100 mg/L tryptophan in a 100 ml shaking flask were inoculated with 20 ⁇ of the corresponding glycerol stock (strain) and cultivated for 48 h at 30°C and 150 rpm on a rotary shaker.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des cellules microbiennes eucaryotes modifiées qui ont été techniquement conçues pour produire des produits de fermentation tels que des acides gras, des 1-alcools, des β-céto-acides et des β-céto-alcools, des β-hydroxyacides, des 1,3-diols, des acides gras trans-A2, des alcènes, des alcanes et leurs dérivés. À cette fin les cellules microbiennes eucaryotes ont été modifiées pour exprimer les enzymes du cycle de β-oxydation des acides gras dans le cytosol de la cellule, en l'absence d'acides gras et en la présence d'une source carbonée non acide gras. Les cellules sont en outre modifiées pour exprimer une voie métabolique de production sous des conditions oxydantes, par l'acétyl-CoA à partir de la source carbonée non acide gras pour alimenter et diriger le cycle de β-oxydation dans le sens de la synthèse biologique et, pour exprimer les enzymes de terminaison pour la conversion des intermédiaires réactionnels du cycle de β-oxydation en le produit de fermentation souhaité. L'invention concerne en outre des procédés oxydants dans lesquels les cellules sont utilisées pour produire les produits de fermentation.
PCT/EP2014/063540 2013-06-26 2014-06-26 Levures techniquement conçues pour la production de substances chimiques de valeur à partir de sucres WO2014207113A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382244 2013-06-26
EP13382244.5 2013-06-26

Publications (1)

Publication Number Publication Date
WO2014207113A1 true WO2014207113A1 (fr) 2014-12-31

Family

ID=48741020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/063540 WO2014207113A1 (fr) 2013-06-26 2014-06-26 Levures techniquement conçues pour la production de substances chimiques de valeur à partir de sucres

Country Status (1)

Country Link
WO (1) WO2014207113A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853602A1 (fr) * 2013-09-25 2015-04-01 Samsung Electronics Co., Ltd Cellule de levure avec bassin de pyruvate accru dans du cytosol et procédé de production d'un métabolite à base de pyruvate l'utilisant
WO2018148849A1 (fr) 2017-02-17 2018-08-23 Hyasynth Biologicals Inc. Procédé et lignée cellulaire pour la production de polycétides dans une levure
WO2019014309A1 (fr) * 2017-07-13 2019-01-17 Verdezyne (Abc), Llc Procédés biologiques pour modifier un flux de carbone cellulaire
JP2020520644A (ja) * 2017-05-17 2020-07-16 プロヴィヴィ インコーポレイテッド 昆虫フェロモンの生成のための微生物及び関連する化合物
US11214818B2 (en) 2016-06-06 2022-01-04 Provivi, Inc. Semi-biosynthetic production of fatty alcohols and fatty aldehydes
US11844353B2 (en) 2015-11-18 2023-12-19 Provivi, Inc. Microorganisms for the production of insect pheromones and related compounds

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003159A1 (fr) 1991-08-02 1993-02-18 Rhone-Poulenc Rorer S.A. Levures recombinantes hautement stables pour la production de proteines recombinantes
US20070022497A1 (en) 2004-10-08 2007-01-25 Basf Plant Science Gmbh Trans-2-enoyl-coa reductase gene of euglena gracilis
WO2008080124A2 (fr) * 2006-12-21 2008-07-03 Gevo, Inc. Production de butanol par une levure métaboliquement modifiée
US20080182308A1 (en) 2005-09-29 2008-07-31 Donaldson Gail K Fermentive production of four carbon alcohols
US20090305363A1 (en) 2008-06-05 2009-12-10 E. I. Du Pont De Nemours And Company Enhanced pyruvate to acetolactate conversion in yeast
US20100248233A1 (en) 2007-07-23 2010-09-30 Dsm Ip Assets B.V. Acetyl-coa producing enzymes in yeast
WO2011149353A1 (fr) 2010-05-27 2011-12-01 C5 Yeast Company B.V. Souches de levure manipulées pour produire de l'éthanol à partir d'acide acétique et de glycérol
WO2011156794A2 (fr) * 2010-06-11 2011-12-15 The Regents Of The University Of California Voies de synthèse pour la synthèse de biocarburants
WO2012050931A2 (fr) 2010-09-28 2012-04-19 The Regents Of The University Of California Production d'alpha-oléfines en utilisant des polycétides synthases
WO2012058606A1 (fr) * 2010-10-28 2012-05-03 Joule Unlimited Technologies, Inc. Procédés et compositions pour biosynthèse recombinante d'oléfines terminales
WO2012109176A2 (fr) 2011-02-07 2012-08-16 William Marsh Rice University Voie de bêta-oxydation inverse
WO2013063513A1 (fr) * 2011-10-27 2013-05-02 The Regents Of The University Of California Production bactérienne de méthylcétones
WO2013076144A2 (fr) * 2011-11-21 2013-05-30 Metabolic Explorer Souches de micro-organismes pour la production de 2,3-butanediol

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003159A1 (fr) 1991-08-02 1993-02-18 Rhone-Poulenc Rorer S.A. Levures recombinantes hautement stables pour la production de proteines recombinantes
US20070022497A1 (en) 2004-10-08 2007-01-25 Basf Plant Science Gmbh Trans-2-enoyl-coa reductase gene of euglena gracilis
US20080182308A1 (en) 2005-09-29 2008-07-31 Donaldson Gail K Fermentive production of four carbon alcohols
US20100062505A1 (en) 2006-12-21 2010-03-11 Gevo, Inc. Butanol production by metabolically engineered yeast
WO2008080124A2 (fr) * 2006-12-21 2008-07-03 Gevo, Inc. Production de butanol par une levure métaboliquement modifiée
US20100248233A1 (en) 2007-07-23 2010-09-30 Dsm Ip Assets B.V. Acetyl-coa producing enzymes in yeast
US20090305363A1 (en) 2008-06-05 2009-12-10 E. I. Du Pont De Nemours And Company Enhanced pyruvate to acetolactate conversion in yeast
WO2011149353A1 (fr) 2010-05-27 2011-12-01 C5 Yeast Company B.V. Souches de levure manipulées pour produire de l'éthanol à partir d'acide acétique et de glycérol
WO2011156794A2 (fr) * 2010-06-11 2011-12-15 The Regents Of The University Of California Voies de synthèse pour la synthèse de biocarburants
WO2012050931A2 (fr) 2010-09-28 2012-04-19 The Regents Of The University Of California Production d'alpha-oléfines en utilisant des polycétides synthases
WO2012058606A1 (fr) * 2010-10-28 2012-05-03 Joule Unlimited Technologies, Inc. Procédés et compositions pour biosynthèse recombinante d'oléfines terminales
WO2012109176A2 (fr) 2011-02-07 2012-08-16 William Marsh Rice University Voie de bêta-oxydation inverse
WO2013063513A1 (fr) * 2011-10-27 2013-05-02 The Regents Of The University Of California Production bactérienne de méthylcétones
WO2013076144A2 (fr) * 2011-11-21 2013-05-30 Metabolic Explorer Souches de micro-organismes pour la production de 2,3-butanediol

Non-Patent Citations (92)

* Cited by examiner, † Cited by third party
Title
"Methods in Yeast Genetics", 2005, COLD SPRING HARBOR LABORATORY PRESS
ABBOT ET AL., APPL. ENVIRON. MICROBIOL., vol. 75, 2009, pages 2320 - 2325
ALTSCHUL, S. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL, S. ET AL.: "BLAST Manual", NCBI NLM NIH BETHESDA
ALTSCHUL, S. F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ANASTASIA KRIVORUCHKO ET AL: "Improving biobutanol production in engineered Saccharomyces cerevisiae by manipulation of acetyl-CoA metabolism", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, vol. 40, no. 9, 13 June 2013 (2013-06-13), pages 1051 - 1056, XP055087006, ISSN: 1367-5435, DOI: 10.1007/s10295-013-1296-0 *
ASANUMA ET AL., CURR. MICROBIOL., vol. 47, 2003, pages 203 - 207
ASANUMA ET AL., CURR. MICROBIOL., vol. 51, 2005, pages 91 - 94
ASANUMA ET AL., CURRENT MICROBIOLOGY, vol. 51, 2005, pages 91 - 94
ASANUMA, CURRENT MICROBIOLOGY, vol. 47, 2003, pages 203 - 207
AUSUBEL ET AL.: "Current protocols in molecular biology", 1987, GREEN PUBLISHING AND WILEY INTERSCIENCE
BECKER ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 10736 - 10742
BERNARD ET AL., PLANT CELL, vol. 24, 2012, pages 3106 - 18
BERNARD ET AL., PLANT CELL., vol. 24, no. 7, 2012, pages 3106 - 18
BOND-WATTS ET AL., NAT CHEM BIOL, vol. 7, 2011, pages 222 - 227
BUIS; BRODERICK, ARCH. BIOCHEM. BIOPHYS., vol. 433, 2005, pages 288 - 296
CLOMBURG; GONZALEZ, BIOTECHNOL BIOENG, vol. 108, no. 4, 2010, pages 867 - 79
CP. KURTZMAN AND J.W. FELL: "The yeasts, a taxonomic study", 1998, ELSEVIER SCIENCE PUBL. B.V.
DELLOMONACO ET AL., NATURE, vol. 476, 2011, pages 355 - 361
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. 1, 1984, pages 387
DUEBER, J.E. ET AL., SCIENCE, vol. 301, no. 5641, 2003, pages 1904 - 1908
EATON ET AL., BIOCHEM. J., vol. 320, 1996, pages 345 - 357
ENGEL ET AL., J. MOL. BIOL., vol. 275, 1998, pages 847 - 859
FLIKWEERT ET AL., YEAST, vol. 12, 1996, pages 247 - 257
GIETZ ET AL., NUCLEIC ACIDS RES., vol. 20, no. 6, 1992, pages 1425
GLOVER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 7558 - 7563
GOODLOE ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 710, 1982, pages 485 - 492
GÜLDENER ET AL., NUCLEIC ACIDS RES, vol. 24, 1996, pages 2519 - 2524
GÜLDENER ET AL., NUCLEIC ACIDS RES., vol. 24, 1996, pages 2519 - 2524
GÜLDENER ET AL., NUCLEIC ACIDS RESEARCH, vol. 24, 1996, pages 2519 - 2524
GULEVICH ET AL., BIOTECHNOL LETT., vol. 34, no. 3, 2012, pages 463 - 9
GUTHRIE ET AL.: "Guide To Yeast Genetics and Molecular Biology", vol. 194, 1991, ACADEMIC PRESS
HARRIS, B.Z. ET AL., BIOCHEMISTRY, vol. 40, no. 20, 2001, pages 5921 - 5930
HELLENBRAND ET AL., BMC BIOCHEM., vol. 12, 2011, pages 64
HENIKOFF; HENIKOFF, PNAS, vol. 89, 1992, pages 915 - 919
HENTIKOFF; HENTIKOFF, PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 10915 - 10919
HILLMER ET AL., FEBS LETT., vol. 21, 1972, pages 351 - 354
HOFFMEISTER ET AL., J. BIOL. CHEM., vol. 280, 2005, pages 4329 - 4338
HOHMANN, MOL GEN GENET., vol. 241, 1993, pages 657 - 666
HOPWOOD; SHERMAN, ANNU. REV. GENET., vol. 24, 1990, pages 37 - 66
HU ET AL., BIOCHEM J., vol. 449, no. 1, 2013, pages 79 - 89
ISHIGE ET AL., APPL. ENVIRON. MICROBIOL., vol. 68, 2002, pages 1192 - 1195
J.A. BARNETT; R.W. PAYNE; D. YARROW: "Yeasts: characteristics and identification, 3rd ed.,", 2000, CAMBRIDGE UNIVERSITY PRESS
JANSEN ET AL., NUCLEIC ACIDS RES., vol. 3J, no. 8, 2003, pages 2242 - 51
KANEHISA, NOVARTIS FOUND SYMP., vol. 247, 2002, pages 91 - 101
KATAOKA ET AL., J. BIOSCI. BIOENG., 2012, Retrieved from the Internet <URL:htip://dx.doi.org/10.1016/j.jbiosc.2012.11.025>
KATAOKA ET AL., JOURNAL OF BIOENEGINEERING, 2012, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/j.jbiosc.2012.11.025>
KIM A.S. ET AL., NATURE, vol. 404, no. 6774, 2000, pages 151 - 158
KOSTER ET AL., ORGANIC GEOCHEMISTRY, vol. 30, no. 11, 1999, pages 1367 - 1379
LAN; LIAO, PNAS, vol. 109, 2012, pages 6018 - 6023
LAN; LIAO, PROC. NATL. ACAD. SCI., vol. 109, 2012, pages 6018 - 6023
LANG; LOOMAN, APPL MICROBIOL BIOTECHNOL., vol. 44, no. 1-2, 1995, pages 147 - 56
LEHTIO; GOLDMAN, PROT. ENGIN. DESIGN & SELECTION, vol. 17, 2004, pages 545 - 552
LENNEN ET AL., BIOTECHNOL BIOENG., vol. 106, no. 2, 2010, pages 193 - 202
MADAN ET AL., EUR. J. BIOCHEM., vol. 32, 1973, pages 51 - 56
MATSUDA ET AL., MICROB CELL FACT., vol. 10, 2011, pages 70
MENDEZ-PEREZ ET AL., APPL ENVIRON MICROBIOL, vol. 77, no. 12, 2011, pages 4264 - 7
MENDEZ-PEREZ ET AL., APPL. ENVIRON. MICROBIOL., vol. 77, 2011, pages 4264 - 4267
MENDEZ-PEREZ ET AL., METAB ENG., vol. 14, no. 4, 2012, pages 298 - 305
MENDEZ-PEREZ, METABOLIC ENGINEERING, vol. 14, 2012, pages 298 - 305
METHODS IN ENZYMOLOGY, vol. 194, 1991, pages 281 - 301
MILLER ET AL., J. BACTERIOL., vol. 138, 1979, pages 99 - 104
MNAIMNEH ET AL., CELL, vol. 118, no. 1, 2004, pages 31 - 44
MURSULA, A.: "A3-A2-Enoyl-CoA Isomerase from the yeast Saccharomyces cerevisiae. Molecular and structural characterization", ACADEMIC DISSERTATION, 2002
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
NGUYEN, J.T. ET AL., SCIENCE, vol. 282, no. 5396, 1998, pages 2088 - 2092
OUD ET AL., MICROBIAL CELL FACTORIES, vol. 11, 2012, pages 131
OVERKAMP ET AL., YEAST, vol. 19, 2002, pages 509 - 520
PERALTA-YAHYA, NATURE, vol. 488, no. 7411, 2012, pages 320 - 8
QIU ET AL., PROC NATL ACAD SCI USA, vol. 109, 2012, pages 14858 - 63
RUDE ET AL., APPL. ENVIRON. MICROBIOL., vol. 7, 2011, pages 1718 - 1727
SAMBROOK; RUSSELL: "Molecular cloning: a laboratory manual (3rd edition),", 2001, COLD SPRING HARBOR LABORATORY PRESS
SAWERS; WATSON, MOL. MICROBIOL., vol. 29, 1998, pages 945 - 954
SCHIRMER, SCIENCE, vol. 329, 2010, pages 559 - 562
SCHULTZ, J. ET AL., NAT STRUCT BIOL., vol. 5, no. 1, 1998, pages 19 - 24
SHARP; LI, NUCLEIC ACIDS RESEARCH, vol. 15, 1987, pages 1281 - 1295
SHEN ET AL., APPL ENVIRON MICROBIOL, vol. 77, 2011, pages 2905 - 15
SHERMAN ET AL.: "Methods Yeast Genetics", 1978, COLD SPRING HARBOR LABORATORY
SMITH; TSAI, NAT PROD REP., vol. 24, no. 5, 2007, pages 1041 - 1072
SPENCER ET AL.: "Yeast Protocols: Methods in Cell and Molecular Biology", 1996, HUMANA PRESS, article "Mutagenesis in Yeast"
STEEN ERIC J ET AL: "Metabolic engineering of Saccharomyces cerevisiae for the production of n-butanol", MICROBIAL CELL FACTORIES, BIOMED CENTRAL, LONDON, NL, vol. 7, no. 1, 3 December 2008 (2008-12-03), pages 36, XP021049875, ISSN: 1475-2859, DOI: 10.1186/1475-2859-7-36 *
TAKAHASHI ET AL., J. BACTERIOL., vol. 149, 1982, pages 1034 - 1040
TEERAWANICHPAN; QIU, LIPIDS, vol. 45, no. 3, 2010, pages 263 - 73
TRONCHONI ET AL., INT J FOOD MICROBIOL., vol. 155, no. 3, 2012, pages 191 - 8
VAN DEN BERG; STEENSMA, YEAST, vol. 13, 1997, pages 551 - 559
VICENTI ET AL., ANAL CHEM., vol. 59, 1987, pages 694
WACH ET AL., YEAST, vol. 10, 1994, pages 1793 - 1808
WEISSMAN; LEADLAY, NATURE REV. MICROBIOL., vol. 3, 2005, pages 925 - 936
WU, X. ET AL., STRUCTURE, vol. 3, no. 2, 1995, pages 215 - 226
ZHANG ET AL., CURR. OP. BIOTECHNOL., vol. 22, 2011, pages 775 - 783
ZHANG ET AL., CURRENT OPINION IN BIOTECHNOLOGY, vol. 22, 2011, pages 775 - 783
ZHENG ET AL., MICROBIAL CELL FACTORIES, vol. 11, 2012, pages 65

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853602A1 (fr) * 2013-09-25 2015-04-01 Samsung Electronics Co., Ltd Cellule de levure avec bassin de pyruvate accru dans du cytosol et procédé de production d'un métabolite à base de pyruvate l'utilisant
US11844353B2 (en) 2015-11-18 2023-12-19 Provivi, Inc. Microorganisms for the production of insect pheromones and related compounds
US11214818B2 (en) 2016-06-06 2022-01-04 Provivi, Inc. Semi-biosynthetic production of fatty alcohols and fatty aldehydes
CN110637088A (zh) * 2017-02-17 2019-12-31 海牙森生物公司 用于在酵母中生产聚酮化合物的方法和细胞系
EP3583217A4 (fr) * 2017-02-17 2021-04-07 Hyasynth Biologicals Inc. Procédé et lignée cellulaire pour la production de polycétides dans une levure
US10975395B2 (en) 2017-02-17 2021-04-13 Hyasynth Biologicals Inc. Method and cell line for production of polyketides in yeast
US11078502B2 (en) 2017-02-17 2021-08-03 Hyasynth Biologicals Inc. Method and cell line for production of polyketides in yeast
US11312979B2 (en) 2017-02-17 2022-04-26 Hyasynth Biologicals Inc. Method and cell line for production of phytocannabinoids and phytocannabinoid analogues in yeast
WO2018148849A1 (fr) 2017-02-17 2018-08-23 Hyasynth Biologicals Inc. Procédé et lignée cellulaire pour la production de polycétides dans une levure
CN110637088B (zh) * 2017-02-17 2024-03-22 海牙森生物公司 用于在酵母中生产聚酮化合物的方法和细胞系
JP2020520644A (ja) * 2017-05-17 2020-07-16 プロヴィヴィ インコーポレイテッド 昆虫フェロモンの生成のための微生物及び関連する化合物
JP7216018B2 (ja) 2017-05-17 2023-01-31 プロヴィヴィ インコーポレイテッド 昆虫フェロモンの生成のための微生物及び関連する化合物
US11866760B2 (en) 2017-05-17 2024-01-09 Provivi, Inc. Microorganisms for the production of insect pheromones and related compounds
US11174488B2 (en) 2017-07-13 2021-11-16 Radici Chimica S.P.A. Biological methods for modifying cellular carbon flux
WO2019014309A1 (fr) * 2017-07-13 2019-01-17 Verdezyne (Abc), Llc Procédés biologiques pour modifier un flux de carbone cellulaire

Similar Documents

Publication Publication Date Title
EP2121949B1 (fr) Production de butanol par une levure métaboliquement modifiée
US20220389433A1 (en) High yield route for the production of compounds from renewable sources
US20180179557A1 (en) Yeast organism producing isobutanol at a high yield
US10704064B2 (en) Recombinant yeast producing 3-hydroxypropionic acid and method for producing 3-hydroxypropionic acid using the same
US9957513B2 (en) Engineering of hydrocarbon metabolism in yeast
US20110076733A1 (en) Cytosolic isobutanol pathway localization for the production of isobutanol
EP2993228B1 (fr) Production d&#39;esters d&#39;acides gras
JP2011512848A (ja) 第一級アルコールを産生する生物
WO2014207113A1 (fr) Levures techniquement conçues pour la production de substances chimiques de valeur à partir de sucres
CA2990939A1 (fr) Organisme de levure produisant de l&#39;isobutanol a un rendement eleve
US20120045809A1 (en) Engineered Microorganisms for the Production of One or More Target Compounds
WO2010057022A1 (fr) Micro-organismes pour la production de méthyléthylcétone et de 2-butanol
WO2010151525A1 (fr) Organismes de levure pour la production d&#39;isobutanol
US20170356016A1 (en) Modified microorganisms and methods for production of useful products
WO2014207087A1 (fr) Production de carburants avancés et de produits chimiques par des levures selon le concept de biocarburants de deuxième génération
WO2014207099A1 (fr) Production biologique anoxique de carburants et de produits chimiques en vrac à partir de matières premières de deuxième génération
WO2014207105A1 (fr) Levure techniquement conçue pour la production de 1-alcools à partir de sucres dans des conditions d&#39;anoxie
US20140295512A1 (en) Ketol-Acid Reductoisomerases With Improved Performance Properties
EP3274449B1 (fr) 6-phosphofructo-1-kinases modifiées qui permettent la croissance par fermentation de cellules recombinées de la levure saccharomyces cerevisiae sur des pentoses
US20240200019A1 (en) Genetically modified yeast cells and methods of use for increased lipid yield
JP2021114931A (ja) 組換え宿主細胞及びそれを用いた有用物質の製造方法
WO2017168161A1 (fr) Enzyme modifiée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14732905

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14732905

Country of ref document: EP

Kind code of ref document: A1